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Summary
Breast cancer is the most common cancer to affect women, and is associated with 
abnormalities in normal growth and proliferation. An alternative way for 
understanding this disease, is to view it as an aberration of normal biological ageing. 
The mitochondrion, telomere nucleo-protein complex and ribosomal DNA, comprise 
the MTR, and link energy production, protein synthesis and DNA damage responses. 
Sirtuins act within the various components o f the MTR, imbalance o f which, may 
result in accelerated ageing, disease and tumorogenesis, a hypothesis first described 
by Shiels and Davies (2003).
Consistent with this viewpoint, altered sirtuin expression is associated with a number 
o f ageing-related diseases, progeroid conditions and malignancies. This observation 
makes their study particularly pertinent for understanding how breast cancer develops 
and progresses from a platform o f aberrant biological ageing. Similarly, the study of 
siituins may be relevant to the study o f breast cancer therapy, as these treatments 
induce cellular senescence and apoptosis, abnormalities o f which are also implicated 
in ageing. Furthermore, the ability o f breast cancer cells to withstand the insult o f 
cytotoxic treatments may be determined by the biological age of tumour cells.
The aim of the research presented within this thesis, was to study breast cancer as an 
aberration of normal biological ageing, with respect to sirtuin expression. It 
specifically sought to determine whether there was an association between the 
transcriptional expression of sirtuins and breast cancer pathogenesis and treatment.
XIX
The transcriptional expression o f sirtuins was initially investigated in primary and 
immortalised mammary epithelial cells, as a function of in vitro growth. In order to 
determine whether changes in biological ageing, observed in primary mammary 
epithelial cells, were pertinent to breast cancer in vivo, transcriptional expression of 
sirtuins was studied in non-malignant and malignant breast tissue biopsies.
Transcriptional studies were also performed to determine the relationship between 
common therapies used for the treatment of breast cancer, namely radiotherapy and 
chemotherapy, and siiiuin expression. Specifically, sirtuin expression was 
investigated in breast cancer cells in response to cellular irradiation and paclitaxel 
treatment.
The expression of SIRT3 and SIRT7, the gene products o f which act at the 
mitochondrion and ribosomal DNA components o f the MTR, was found to increase as 
cells underwent replicative ageing. Similarly, the transcriptional expression o f SIRT3 
and SIRT7 was elevated in lymph node positive breast cancer biopsies compared to 
non-malignant breast biopsies. In contrast, SIRTl and SIRT2 showed no difference in 
expression in either replicative ly ageing cells or between malignant and non- 
malignant breast biopsies. The increased SIRT3 and SIRT7 expression observed in 
lymph node positive breast cancer biopsies, suggests that tumours associated with 
more invasive disease display perturbation within components of the MTR, indicative 
o f increased biological ageing..
In breast cancer cells exposed to irradiation and paclitaxel treatment, SIRT2 and 
SIRT7 transcriptional expression was found to increase. In contrast, SIRTl and SIRT3
XX
expression remained relatively unchanged. The increased expression o f SIRT2 and 
SIRT7 in response to these treatments, suggests that these therapies target components 
of the MTR that are associated with mitotic growth arrest. In particular, SIRT7, is 
associated with ageing and indicates that these agents induce ageing in these tumour 
cells.
In summary, this research shows aberrant sirtuin expression to be a feature of primary 
mammary epithelial cell senescence, breast cancer pathogenesis and damage 
responses in breast cancer cells, secondary to ionising radiation and paclitaxel 
therapy.
XXI
Chapter 1 
Introduction
1.1 Breast cancer
Breast cancer is the most common cancer to affect women with over 40,000 new cases 
being detected and around 13,000 women dying from the disease each year (CancerStats, 
2005). Breast cancer represents a heterogeneous group of diseases that display a wide 
spectrum of behaviour ranging from slow growing, non-metastatic disease with an 
excellent prognosis through to fast growing disease with a propensity for early metastasis 
and rapid death. Traditionally, tumour stage and grade have been useful in predicting 
prognosis but fail to predict the clinical course o f the disease. The identification of factors 
that can help understand the natural history of breast cancer as well as identify 
appropriate treatments is therefore a major area of cancer research.
1.1.1 Tumour Biology
Studies looking at the molecular biology of breast cancer seek to gain a better 
understanding of this disease to aid diagnosis and management. The incidental discovery 
by Beatson, that oophorectomy resulted in breast cancer remission, led to the 
understanding that many breast cancers are oestrogen dependent and resulted in the 
development of hormone therapies that include tamoxifen and peripheral aromatase 
inhibitors. More recently, upregulation of telomerase and altered ERBB2 gene expression 
have been shown to be features o f breast cancer (Russo and Russo, 2003).
An improved understanding of breast cancer biology provides an alternative way of 
predicting tumour behaviour, distinct from those that have looked at features such as 
tumour size, histological grade and nodal status. Recent studies using DNA microarrays 
suggest that breast cancer can be classified into at least four distinct forms based upon the 
hierarchical clustering of micro array data. These classes are Luminal/ER positive, Basal, 
ERBB2 positive and Normal-like types (van 't Veer et al., 2002). This classification has 
been shown to predict prognosis independent o f traditional features such as age, lymph 
node and estrogen receptor (ER) status (Sorlie et al., 2001, van 't Veer et al., 2002). This 
system also indicates that tumour behaviour may be understood outwith factors such as 
tumour growth and proliferation. An example of this is the discovery that ERBB2 
positive tumours display lower levels of proliferation than Luminal and Normal-like 
types, despite being associated with a poorer prognosis.
This observation highlights the deficiency of breast cancer studies that have focused on 
transformation as a result of abnormalities in normal growth and proliferation. It is for 
this reason that the study of breast cancer as an aberration of normal biological ageing is 
particularly pertinent. Studying breast cancer from this perspective provides an 
alternative platform for understanding the disease. Specifically, a better understanding of 
the molecular processes involved in sensing, assessing and signalling cellular damage 
might be informative in such a context (Shiels and Davies, 2003).
1.1.2 Cancer therapy
The relationship between ageing and breast cancer may reflect the accumulation of 
cellular damage over a cell’s lifespan, as well as a decline in the cell’s ability for damage 
repair. Similarly, the ability of breast cancer cells to withstand the insult of cytotoxic 
therapies may also be influenced by genes involved in biological ageing. Therapies 
commonly used for the treatment o f breast cancer, including radiotherapy and 
chemotherapy, often result in senescence and apoptosis, processes that also contribute to 
ageing and the pathogenesis of age-related diseases (Shay and Roninson, 2004, Shiels 
and Davies, 2003). Understanding the biology of breast cancer therapies, may help in 
tailoring treatment to individuals and their disease biology, as well as helping in the 
development of new therapies.
Genes central to the control of biological ageing include those that maintain telomere 
structure, control protein synthesis and regulate mitochondrial energy production. The 
SIR2, silent information regulator, family of genes have been hypothesised to link the 
functions of the mitochondrion, telomere nucleo-protein complex and ribosome 
production (the MTR) and contribute to a wide range of ageing related diseases including 
cancer (Shiels and Davies, 2003, Shiels, 1999).
The functions of Sir2 have been best characterised in the baker’s yeast, Saccharomyces 
cerevisiae, and include silencing at telomeres, DNA repair, cell-cycle control and the 
regulation of ageing (Guarente, 1999). These functions bear close parallels to the function
of Sir2 orthologues, known as sirtuins, in humans. An understanding of sirtuin biology 
may, therefore, help us in understanding how breast cancer develops and progresses from 
a platform of biological ageing.
1.2 SIR2
The SIR2 family of genes comprises a large group of highly conserved genes in 
organisms ranging from bacteria to man (Brachmann et al., 1995, Frye, 1999). As 
previously mentioned, SIR2 in S. cerevisiae is the best characterised of these and 
functions in a variety of essential cell processes, ranging from silencing at telomeres and 
mating type loci, chromosome segregation, DNA repair, regulation of the cell-cycle, 
meiosis and ageing (Guarente, 1999). The process of silencing and each of these 
functions are explored below.
1.2.1 Silencing
Unlike promoter, or sequence-specific transcriptional control of genes, silencing is the 
reversible, heritable, transcriptional repression o f large chromosomal domains regulated 
in a position-dependent manner (Loo and Rine, 1995). Classic examples of this include 
mammalian X chromosome inactivation and Drosophila eye colour mosaicism (Lyon, 
1961).
The Sir2 proteins are thought to perform this function by enzymatically modifying 
histone proteins within chromatin (Guarente, 1999). Indeed, silenced heterochromatin, 
found at telomeres, centromeres and within ribosomal DNA, contains hypoacetylated 
histones, unlike its transcriptionally active, euchromatin counterpart (Braunstein et al., 
1993, Loo and Rine, 1994, Bi and Broach, 1997). This heterochromatin is compact, with
restricted access to transcription, replication and recombination machinery (Tse et a l, 
1998). Recent studies, however, suggest that Sir2-mediated transcriptional repression 
does not occur simply by preventing access to transcriptional machinery, but occurs 
downstream from gene activator protein binding (Chen and Widom, 2005).
1.2.2 Biochemistiy
1.2.2.1 Structure
The Sir2 protein family has been sub-classified into five classes, I, II, III, IV and U, based 
upon sequence homology (Frye, 2000).
In S, cerevisiae, four additional Sir2-related proteins exist, encoded by HSTl-4 
(homologues of sir two). All of the Sir2 proteins possess a specific C-terminal core region 
of around two hundred and seventy five amino acid residues that is widely conserved and 
vital for silencing activity (Brachmann et al., 1995, Cockell and Gasser, 1999).
Four major parts constitute the Sir2 structure, a Rossman fold, a flexible loop and helical 
and zinc-binding domains (Finnin et al., 2001, Min et al., 2001). The enzymatic co­
substrate, NAD, binds in a pocket between the helical domain and Rossman fold, and is 
flanked by the loop (Figure 1.1).
Figure 1.1 Structure of Sir2. The figure shows a schematic representation of the Sir2 
protein interacting with its NAD co-substrate and acetyl lysine histone substrate. [Figure 
adapted from (Marmorstein, 2004)]
Zn^^ binding and 
Helical domains
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1.2.2.2 Enzymatic activity
The Sir2 proteins are class III histone deacetylases (Tanny et al., 1999, Frye, 1999) and 
have an NAD-dependent function (Imai et al., 2000, Landiy et al., 2000, Smith et al., 
2000, Tanner et al., 2000). Unlike the other deacetylase classes, they do not have a zinc 
catalysed function and are not inhibited by trichostatin. The Sir2-dependent deacetylation 
reaction is tightly coupled with NAD cleavage and the formation of an (7-acetyl-ADP- 
ribose (OAAR) product (Figure 1.2).
Figure 1.2 Mechanism of Sir2 enzymatic activity.
Substrate + Sir2 + NAD^ i C> d-acetyl-ADP-ribose + Hypoacetylated + Nicotinamide
Substrate
Enzyme Co-substrate
The Sir2 proteins also possess ADP-ribosyltransferase activity that may be important in 
DNA repair (Kreimeyer et al., 1984, Pero et al., 1985). The production o f the OAAR 
metabolite may itself, perform an important function (Tanner et a l,  2000). Indeed, 
OAAR has been shown to play an important role in delaying/blocking oocyte maturation 
as well as embryo cell division in blastomeres (Borra et a l, 2002).
Finally, reversible protein deacetylation is known to be an important post-translational 
modification in the regulation of many biological processes (Kouzarides, 2000, Sterner
and Berger, 2000). Although Sir2 activity was originally thought to be restricted to the 
acetyl lysine residues on histones three and four in nucleosomes (Braunstein et at., 1993), 
the discovery of Sir2 orthologues in organisms that do not have histones, as well as 
orthologues with extranuclear locations (Zemzoumi et al., 1998, Afshar and Murnane, 
1999, Period et al., 2001, Vergnes et al., 2002), suggests that targets of Sir2 also include 
non-histone proteins. Indeed, Sir2 orthologues have been shown to deacetylate a various 
substrates, including p53 in humans (Luo et al., 2001, Vaziri et al., 2001) and the 
TAF168 subunit of the TATA-box binding protein-containing factor in mice (Muth et al., 
2001).
1.2.2.3 Nicotinamide
Nicotinamide, a form of vitamin Bg^  is a product of the Sir2 deacetylase reaction and 
potent non-competitive inhibitor of Sir2, NAD-dependent deacetylase activity (Landry et 
a l, 2000). It is also a substrate used by nicotinamidase, encoded by PNCl, for NAD 
synthesis. Although the 1:1 requirement of NAD for Sir2 deacetylase activity predicts 
that NAD levels may be a rate limiting component for its activity, cellular NAD levels 
remain relatively stable. In fact, no change in overall NAD levels are observed in cells 
lacking PNCl despite a resultant fall in Sir2-dependent silencing (Sandmeier et a l,
2002). This observation suggests that it is nicotinamide rather than NAD levels that 
determine the degree of SIR2 silencing. However, it may be that specific compartmental 
changes in NAD, or changes in the levels of the NAD pre-cursor, nicotinic acid 
mononucleotide, regulates Sir2 activity (Bitterman et a l, 2002).
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1.2.3 Functions
SIR2 provides a functional link between the telomere and nucleolar ribosomal DNA 
cluster integrity, thus impacting on ribosome production and enabling the cell to respond 
to stress-induced redox state changes within the mitochondrion (Guarente, 1999). 
Consequently, damage responses in the cell can be modulated to match the degree of 
insult. The functions of Sir2, as a consequence of endogenous and exogenous stressors, 
are explored below.
1.2.3.1 Silencing at mating type loci
Sir2 silencing activity was originally described for S. cerevisiae, and confers it with the 
capability of expressing two very distinct mating phenotypes, depending on nutritional 
availability. Silencing at the mating type loci, homothallic left, HMLa, and homothallic 
right, HMRa, on chromosome three results either in the expression of the a or a mating 
phenotype (Rine and Herskowitz, 1987). If  there are mutations in SIR2, silencing at both 
o f these regions is lost, with resultant co-expression of the a and a mating type genes and 
sterility in haploid strains (Kaeberlein et a i, 1999)
1.2.3.2 Telomeric silencing
Although the majority of Sir2 is found within the nucleolus (Gotta et a i, 1997), Sir2 
proteins, along with other telomere binding proteins, are also visualised at the telomeres 
(Figure 1.3) (Moretti et al., 1994). Sir2 helps preserve and stabilise telomeres and also 
suppress the transcription of reporter genes placed at telomere-proximal sequences, a
11
process known as positional effect variegation (PEV) (Palladino et al., 1993, Gottschling 
et al., 1990). SIR2 mutations therefore result not only in a loss of PEV and constitutive 
expression of telomeric reporter genes, but also in telomere shortening (Aparicio et al., 
1991, Palladino et al., 1993).
Figure 1.3 Telomeric nucleo-protein complex. The figure shows the interaction of Sir2 
with the DNA-protein complex and the telomerase enzyme at the telomere. Collectively 
these structures form part of the telomeric nucleo-protein complex [Figure adapted from 
Hodes et a i ,  (2002)]
Telomere DNA-protein complex Telomerase
-RAD50Tankyrase
Dyskenn
ü C G m A ü C
GTTAG 
C - 5 »
TRF1 T R F2r^R A P1
SIR COMPLEX
template StayL22
The Sir2 protein complex interacts with telomeres via a set of DNA binding factors, 
including Rapl and the Ku heterodimer. Rapl, has itself been shown to bind directly to 
telomere-repeat sequences (Moretti et a i ,  1994). As with Sir mutants, Ku mutants also 
display a loss of telomeric silencing and have a more splayed telomeric arrangement 
(Laroche et al., 1998).
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1.2.3.3 DNA repair
Sir2 proteins are also required for the repair of double stranded breaks (DSB) in DNA. 
Following the initial recruitment of Ku and Rapl, the Sir protein complex redistributes 
from telomeres to sites of DSB (Martin et al., 1999, Mills et al., 1999), Ku may bind the 
ends of the DSBs, protecting them from nucleolytic degradation, thereby allowing Sir 
proteins to generate heterochromatin to constrain the ends and facilitate end joining by 
ligase activity (Tsukamoto et al., 1997, Jackson, 1997).
Despite DSBs in yeast being repaired mainly by an homologous recombination (FIR) 
pathway, Sir2-mediated repair occurs by non-homologous end joining (NFJEJ) (Critchlow 
and Jackson, 1998, Tsukamoto et al., 1997). NHEJ, however, is the main method of DSB 
repair in mammals. Yeast cells harbouring mutant SIR2 display a significant decrease in 
NHEJ, less efficient DSB ligation and increased radio sensitivity (Astrom et al., 1999, 
Martin et al., 1999, Tsukamoto et al., 1997).
1.2.3.4 Ageing
Sir2 is also involved in the silencing of the ribosomal DNA (rDNA) cluster on 
chromosome twelve. This DNA contains one to two hundred repeats of a nine kilobase 
unit, which encodes ribosomal RNA (rRNA) that is transcribed and assembled into 
ribosomes within the nucleolus (Shaw and Jordan, 1995). Sir2 has been shown to relocate 
to the nucleolus with increasing age, and Sir2 concentration is directly related to lifespan 
(Kaeberlein et al., 1999).
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HR-mediated repair of DSB occurring within the rDNA results in the formation of 
extrachromosomal ribosomal DNA circles (ERC) (Park et a i ,  1999). These structures are 
segregated in a biased manner towards the yeast mother cell. Once accumulation of these 
ERCs reaches a critical level the mother cell can no longer divide (Figure 1.4) (Sinclair 
and Guarente, 1997).
Figure 1.4 Nucleolar ERC formation and preferential segregation to mother cells.
The figure shows the preferential segregation of extrachromosomal ribosomal DNA 
circles (ERC) to the mother cells with cell division.
Nucleus
M other C ell
D au gh ter  C ell
Sir2 is involved in transcriptional silencing at the rDNA as well as in recombinational 
suppression, thus preventing the accumulation of ERCs (Gottlieb and Esposito, 1989, 
Bryk et al., 1997, Smith and Boeke, 1997). Loss of function mutations in SIR2 results in 
an increase in ERC generation and cell ageing.
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1.2.3.5 Cell cycle
The ability of S. cerevisiae to initiate DNA replication requires the assembly of pre- 
replicative complexes (pre-RCs). The origin replication complex involved in formation of 
silenced chromatin, is essential for DNA replication and binds to and recmits factors to 
pre-RCs. This results in DNA unwinding and recruitment of polymerases, and thereby 
allows DNA replication. In a study by Pappas et a l, (2004), Sir2 was shown to inhibit 
pre-RC assembly and therefore DNA replication. Sir2 function prevents chromosomal 
DNA replication, thereby preventing an increase in ploidy and resultant genomic 
instability.
Sir2 along with the net I, cdcl4 and nanl proteins forms the RENT (regulator of nucleolar 
silencing and telophase exit) complex, that controls cell-cycle progression (Shou et al., 
1999, Straight et al., 1999). CdcI4 functions to inactivate cyclin-dependent kinase (cdk) 
activity at the end of mitosis. Cdcl4 is kept anchored in an inactive state within the 
nucleolus by the RENT complex but can redistribute into the cytoplasm, thereby allowing 
re-entry into the Gi phase. Cells lacking CdcI4 arrest have spindle abnormalities, 
chromosomal defects and genome instability (Pringle and Haitwell, 1981).
1.2.3.6 Meiosis
Sir2 also functions in a meiotic checkpoint to monitor chromosome segregation. The 
pch2 protein has been shown to be required for the pachytene checkpoint of meiosis as 
yeast mutants, deficient in pch2, are able to bypass this pachytene phase arrest. These 
mutants can sporulate and undergo meiotic recombination (Sym et al., 1993, San-
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Segundo and Roeder, 1999). Nucleolar co-localisation with Sir2 is thought to be 
necessary for the action of pch2. In Sir2 mutants, nucleolar pch2 co-localisation is lost 
and the meiotic checkpoint disrupted resulting in an increased rate of meiotic 
recombination.
1.2.4 Caloric restriction
The diverse functions of Sir2 in yeast are closely linked and reflect the central role that 
Sir2 plays in growth and proliferation, DNA damage repair and ageing in response to 
exogenous sti'esses and nutritional availability. One of the most exciting discoveries to be 
made in this regard is that caloric restriction (CR) results in a Sir2-dependent 
prolongation of lifespan (Howitz et a l, 2003).
This lifespan extension can be explained by the attenuation of oxidative damage and 
changes in fuel utilisation. The reliance of Sir2 on its NAD co-substrate, is central to this 
lifespan extension. Increased mitochondrial NAD, as a result of CR, may result in a 
concomitant increase in Sir2 activity at telomeres and within the nucleolar rDNA (Lin et 
a l, 2002). The decrease in oxidative stresses may also result in a fall in DNA damage, 
and increased concentration of Sir2 at telomeres and the nucleolus.
Interestingly, the plant polyphenol, resveratrol, found in large quantities in red wine, has 
been found to be a potent Sir2 activator and can, like CR, increase DNA stability and 
extend lifespan in yeast (Howitz et a l, 2003).
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1.3 Sirtuins
In mammals, seven Sir2-like proteins, termed siiinins, have been discovered (Table 1.1) 
(Brachmann et al., 1995, Frye, 1999, Frye, 2000). Like Sir2, all contain a core domain 
comprising approximately two hundred and seventy five amino acid residues. Based on 
molecular phylogenetic analyses of both prokaryotic and eukaryotic sirtuins, sirtuins have 
been designated into five distinct classes, classes U and Ï-1V (Frye, 2000). The seven 
human sirtuins belonging to classes 1-IV.
The human sirtuins possess variable NAD-dependent deacetylase and ADP- 
ribosyltransferase enzymatic activities (Schwer et a i, 2002). Sirtuins also vary in their 
intracellular location and targeting, with some members being predominantly nuclear, 
cytoplasmic or mitochondrial (Figure 1.9). Although human sirtuins are expressed in a 
wide variety of human tissue (Michishita et a l, 2005), they show a preponderance for 
metabolically active tissue, such as the heart and skeletal muscle.
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1.3.1 Sirtuin 1
Based on protein sequence homology analysis, Sirtuin 1 (Sirtl) is the closest orthologue 
of yeast Sir2 (Imai et al., 2000, Frye, 1999). It is also the best characterised of the human 
sirtuins, unlike the remainder of which little is still known.
Like yeast Sir2, Sirtl exhibits predominantly nuclear localisation and also interacts with 
and deacetylates histones, to promote the formation of repressive facultative 
heterochromatin. (Imai et al., 2000, Senawong et al., 2003, Vaquero et al., 2004). Sirtl 
also has a non-histone substrates including p53, PCAF, p300, MyoD, the Foxo 
transcription factors, NF-kB and E2F1 (Yeung et al., 2004, Vaziri et al., 2001, Luo et al., 
2001, Cohen et al., 2004a, Fulco et al., 2003, Motta et al., 2004, Brunet et al., 2004, van 
der Horst et al., 2004, Kobayashi et al., 2005, Wang et al., 2006). In addition, Sirtl 
interacts with the Hesl/Hey2 factors, CTIP2 and PPAR-y (Takata and Ishikawa, 2003, 
Senawong et al., 2003, Picard et al., 2004). Interaction of Sirtl with these substrates, 
allows Sirtl to be recruited to chromatin regions and specific promoters, to influence the 
transcription of other genes. Through these interactions, Sirtl is thought to function in a 
wide variety of important cell processes, including apoptosis (Luo et al., 2001, Vaziri et 
al,, 2001, Cohen et al., 2004a), development and embiyogenesis (Sakamoto et al., 2004, 
Fulco et al., 2003, Cheng et al., 2003, Takata and Ishikawa, 2003, McBurney et al.,
2003), glucose and fat metabolism (Moynihan et al., 2005, Nemoto et al., 2005, Rodgers 
et al., 2005), muscle differentiation (Fulco et al., 2003, Machida and Booth, 2004) and 
axonal degeneration (Araki et a l, 2004).
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1.3.1.1 Apoptosis
Sirtl is thought to play an important regulatory role in mediating cell survival by 
preventing p53-mediated growth arrest, senescence and apoptosis. Sirtl mediates 
apoptosis in response to stimuli including oxidative damage, ionising radiation and 
exposure to TNFa (Luo et al., 2001, Vaziri et al., 2001, Yeung et al., 2004). It is thought 
to do this through p53-dependent and independent pathways (Figure 1.5).
Figure 1.5 Putative role of S irtl in the DNA damage response. This figure is an 
overview of the interactions of Sirtl with key players in the DNA damage response.
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E2F1
ATM Sirtl FOXO
Damaged cells 
undergo growth arrest, 
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1.3.11.1. p53
Human Sirtl has been shown to be involved in the negative regulation of p53 in the 
presence of both oxidative stress (Luo et a l, 2001) and y-radiation induced damage 
(Vaziri et a l,  2001). Control of p53 activity primarily involves post-translational 
modifications, such as phosphoiylation and acétylation (Appella and Anderson, 2000). In 
the absence of DNA damage, Mdm2 is the major negative regulator for p53 (Prives and 
Hall, 1999, Vogelstein et al., 2000). In response to DNA damage, ATM phosphorylates 
p53, resulting in its stabilisation and activation, thereby preventing it from binding Mdm2 
(Lambert et a l, 1998). ATM also phosphorylates Mdm2, decreasing its inhibitory 
potential on p53. ATM may also, like its yeast MECl kinase counterpart, participate in 
the recruitment of Sirtl to sites of DNA damage. In addition, the tumour suppressor HICl 
represses SIRTI transcription permitting p53 to mediate growth arrest and apoptosis 
(Chen et a l, 2005). In response to DNA damage, Sirtl binds, deacetylates and thereby 
inhibits p53 activity (Figure 1.5) (Vaziri et al., 2001, Luo et al., 2001). This is a simplistic 
model, as Sirtl has also been shown to have binding sites for p53, that can itself stimulate 
Sirtl transcription, in a Foxo-dependent manner (Nemoto et a l, 2004).
1.3.1.1.2. FOXO transcription factors
In response to oxidative stress, Sirtl-mediated deacetylation of the Foxo forkhead family 
of transcription factors also occurs (Motta et al., 2004, Greer and Brunet, 2005, Brunet et 
al., 2004, van der Horst et al., 2004, Yang et al., 2005). The Foxo factors induce the 
transcription of wide variety of genes including MnSOD, GADD45, p27^^^\ Bim and Fas 
(Daitoku et al., 2004, Brunet et al., 2004). These genes are involved in the oxidative
2 1
stress response, DNA repair, cell-cycle control and apoptosis respectively (Accili and 
Arden, 2004), The effects of Sirtl on Foxo-controlled genes vary between tissues and 
range from their activation to repression. Overall, it appears that Sirtl activity results in a 
decrease in Foxo3-mediated apoptosis, an increase in Foxo3-mediated DNA repair and 
cell-cycle arrest and an increase in both Foxol and Foxo4-mediated stress resistance 
(Motta et al., 2004, Brunet et al., 2004, van der Horst et al., 2004, Kobayashi et al., 2005, 
Daitoku et al., 2004). The overall effect is to shift Foxo-induced responses away from 
apoptosis towards cell-cycle arrest, perhaps allowing cells time to repair the DNA 
damage and detoxify free radicals. Through its interaction with the Foxo factors, Sirtl 
mediates stress resistance in a p53-independent manner (Figure 1.5). Evidence supporting 
this comes fiom the observation that apoptosis in cells lacking SIRTI is only partially 
rescued by transfection with a dominant negative p53 mutant (Vaziri et a l, 2001) and, 
that in cells lacking functional p53, the Sirtl activator, resveratrol, can still increase 
resistance to y-radiation (Howitz et a l, 2003).
I.3.I.I.3. Ku70 (G22P1)
The p53 apoptotic response is multifaceted, as it activates numerous pro-apoptotic genes 
including Bax and PUMA. Bax is normally rendered inactive by its tight association with 
the Ku70 protein, a component of the Ku DNA helicase encoded by G22P1. In response 
to acute cell damage or stress, Ku70 is acetylated by the CREB-binding protein (CBP) 
and the acetyltransferase, p300/CBP-associated factor (PCAF), disrupting the Ku70-Bax 
association. The Bax protein then initiates apoptosis by relocalizing from the cytoplasm 
to the outer mitochondrial membrane. The result is the release of cytochrome and
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downstream events including caspase activation (Cohen et al., 2004a, Bossy-Wetzel and 
Green, 1999). Sirtl deacetylates residues on Ku70, keeping Bax sequestered from the 
mitochondria and thereby prevents apoptosis (Figure 1.5).
1.3.1.1.4. E2F1
The E2F family of transcription factors have roles in regulating cell proliferation and 
apoptosis (Nahle et a l, 2002). Similar to ATM and p53, DNA damage also results in the 
activation of the E2F1 apoptotic factor (Lin et a l, 2001). In a negative feedback loop, 
E2F1, induces SIRTI expression, which binds to and inhibits E2F1 activity (Figure 1.5) 
(Wang et a l, 2006). Inhibition of Sirtl results in an increase in E2F1-mediated apoptosis. 
Sirtl may prevent E2F1-mediated apoptosis, thereby allowing DNA damage repair.
1.3.1.1.5. NF-kB
Although Sirtl provides a survival advantage by binding, deacetylating and thereby 
decreasing p53, Foxo and Ku70-mediated apoptosis, it is also Icnown to deacetylate and 
inactivate NF-kB, thereby sensitising cells to TNFa-induced apoptosis (Yeung et a l,
2004).
NF-kB, is responsible for the regulation of genes that control cell survival. It exists as a 
heterodimer, composed of p50 and RelA/p65 polypeptides. Within the cytoplasm it is 
normally bound to members of the IkB family of inhibitory proteins. Once activated NF- 
kB is released into the nucleus where it enhances transcription by tethering histone 
acetyltransferases (HAT) that result in an open chromatin structure. Histone deacetylases
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(HDAC) including Sirtl inhibit NF-kB transcription (Yeung et a l, 2004). Sirtl does this 
by associating with and deacetylating the RelA/p65 subunit of NF-kB. Treatment with, 
resveratrol, a sirtuin activator and known inhibitor of NF-kB transcription, results in a fall 
in the transcription of genes, including a fall in the anti-apoptotic cIAP-2 gene following 
TNFa stimulation. The cIAP-2 gene product inhibits TNFa-induced caspase activation 
and therefore resveratrol results in sensitisation to TNFa-induced apoptosis. This effect is 
Sirtl-dependent, as loss of Sirtl expression completely inhibits this TNFa-induced 
apoptosis (Figure 1.5).
1.3.1.2 Growth and differentiation
Sirtl expression influences cell survival and division in the face of stress and signals for 
terminal differentiation. Specifically, Sirtl is able to inhibit skeletal muscle gene 
expression and differentiation. Sirtl does this by interacting with and enhancing the 
transcriptional repression of Hesl and Hey2, members of Flairy-related protein 
subfamilies (Takata and Ishikawa, 2003). These are transcriptional repressors that prevent 
cellular differentiation (Fisher and Caudy, 1998). Sirtl may also act by being recruited to 
chromatin by the Hesl and Hey2 DNA-binding factors, thereby allowing direct 
enzymatic modification of histones by Sirtl. Finally Sirtl may prevent muscle 
differentiation by associating with and deacetylating PCAF, thereby causing an increase 
in the interaction between Heyl and the muscle differentiation transcription factor, 
MyoD, and also by repressing MyoD directly by interacting with the two MyoD 
regulated promoters, MHC and myogenin (Fulco et a l, 2003).
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Increased levels of Sirtl are also seen in satellite muscle cells from older animals. These 
muscle cells play a role in the regeneration and repair of damaged muscle (Hawke and 
Garry, 2001). In aged rats, there is lower muscle satellite cell proliferation and in a study 
looking at the protein expression in muscle cells from older rats, p21, p53, Sirtl and 
Foxol were all found to be higher than in cells from younger animals (Machida and 
Booth, 2004). Rather than controlling muscle cell growth, increased Sirtl in older 
animals may reflect the cells attempt at limiting the p53 and Foxo-mediated apoptosis in 
muscle cells, as a result of ageing.
1.3.1.3 Glucose and fat metabolism
Skeletal muscle is also the primary site of insulin-mediated glucose uptake and Sirtl in 
muscle tissue may influence glucose uptake in response to food intake, fasting and 
exercise. In pancreatic (3 cells of transgenic mice that overexpress SIRTI, there is an 
improvement in glucose tolerance and enhanced insulin secretion in response to glucose 
stimulation (Moynihan et al., 2005). Sirtl does this by repressing expression of the 
mitochondrial uncoupling protein, UCP-2 (Bordone et al., 2006). SIRTI deacetylation of 
Foxol also promotes resistance to oxidative stress in pancreatic j3 cells (Kitamura et a i,
2005).
Sirtl modulates hepatic gluconeogenesis and glycolysis in response to fasting. In this 
situation, Sirtl expression increases in a Foxo3a and p53-dependent manner (Nemoto et 
a l, 2004). Sirtl then deacetylates and decreases the expression of the mitochondrial 
biogenesis coactivator, PG C -la, a regulator of cellular metabolism in response to fasting
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(Nemoto et a i, 2005), Sirtl thereby induces gluconeogenic genes and glucose release and 
modulates PG C -la mediated repression of glycolytic genes (Rodgers et a i,  2005).
Genes regulating fat development and mobilisation are also under the control of S irtl. In 
response to food deprivation, Sirtl promotes fat mobilisation in white adipocytes by 
binding to and repressing genes controlled by the fat regulator, peroxisome proliferator- 
activated receptor-y, PPAR-y. It does this by binding with its cofactors, nuclear receptor 
co-factor, NcoR, and the silencing mediator of retinoid and thyroid hormone receptors, 
SMRT. The result is the mobilisation of fatty acids from white adipocytes and decreased 
lipogenesis and fat storage. Overexpression of Sirtl, as well as treatment with resveratrol 
results in an increased Sirtl-mediated reduction in fat (Picard et a l, 2004).
Sirtl also deacetylates the metabolic enzyme acetyl co-synthetase 1, AceCSl, resulting in 
an increase in acetyl CoA synthesis from free acetate (Hallows et a l, 2006). Although the 
significanee of this acetyl CoA synthesis is unclear, one of its uses may be in fat 
metabolism (Figure 1.7).
1.3.1.4 Embryonic development
Multi-cellular organisms employ apoptosis widely during embryogenesis and have 
adapted this mechanism to rid the organism of redundant tissue during organogenesis. 
The expression of Sirtl is particularly high during embryogenesis. In animal studies, 
Sirtl levels were highest in early embryogenesis and, in particular, in embryonic heart 
and neural tissue. Furthermore, transgenic mice deficient in SIRTI, display cardiac and
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neurological defects (McBurney et a l, 2003, Cheng et a l, 2003). These obsei-vations 
suggest that Sirtl may play a role in both cardio- and neurogenesis.
Siitl enhances the transcriptional repression of the Hesl and Hey2 transcription factors. 
Hesl and Sirtl are both expressed in neural precursor cells and, both their expression 
decreases during neurogenesis (Sasai et a l, 1992, Sakamoto et a l, 2004). Hesl is though 
to prevent neural differentiation, therefore, it may be speculated that downregulation of 
both Hesl and Sirtl may be necessary for normal neural development. Hey2 is also 
detectable in the primitive ventricle during embiyogenesis and is thought to regulate its 
morphogenesis (Leimeister et a l, 1999). Here too, Sirtl may interact with Hey2 to 
perform this function. Sirtl may affect organogenesis by either fiilfilling an antiapoptotic 
function or by regulating the transcription of other genes that control growth and 
differentiation.
1.3.1.5 Axonal degeneration
Axonal degeneration is an active process and is involved in physiological and 
pathological conditions including Alzheimer’s disease, Parkinson’s disease and nerve 
injury (Raff et a l, 2002). NAD and Sirtl have been shown to prevent axonotomy- 
associated axonal degeneration (Araki et a l, 2004). Treatment with sirtuin inhibitors 
prior to injury decreased this protection and, pre-treatment with the Sirtl activator 
resveratrol, replicated the axonal protection seen with NAD.
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1.3.1.6 Haematopoeisis
Sirtl is also implicated in transcriptional repression mediated by chicken ovalbumin 
upstream promoter transcription factor (COUP-TF)-interacting protein 2, CTIP-2 
(Senawong et a i, 2003). CTIP-2 itself enhances the transcriptional repression of COUP- 
TF. The CTIP proteins were originally identified in cells of lymphoid origin and are 
implicated in normal haematopoietic cell development. Moreover, the CTIP proteins are 
implicated in the aetiology of haematopoietic malignancies.
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1.3.2 Sirtuin 2
Sirtuin 2 (Sirt2) is closely related to yeast Hst2 and, is also a predominantly cytoplasmic 
protein (Afshar and Murnane, 1999, Perrod et al., 2001). As with Sirtl, it possesses both 
NAD-dependent deacetylase and ADP ribosyltransferase activities (Frye, 1999). It has 
been shown to interact with and deacetylate the a-tubulin subunit of microtubules (North 
et al., 2003, Dryden et al., 2003).
Microtubules are formed by the polymerization of a -  and (3-tubulin units and play an 
important role in cell shape, motility, intracellular transport as well as division (Nogales, 
2000). Many post-translational modifications of micro tubules are known to occur 
including both acétylation and deacetylation (Pipemo et al., 1987, Nogales et al., 1999).
1.3.2.1 Cell cycle
Sirt2 has been shown to dramatically increase in abundance within the cytoplasm during 
mitosis. Indeed, hyperphosphoiylated, activated forms of Sirt2 are seen to be confined to 
the M phase of the cell-cycle at the G2/M phase transition. Overexpression of the 
enzymatically active Sirt2 results in a delay in cell-cycle progression (Diyden et a l,
2003). Deacetylation of microtubules in the spindle apparatus result in arrest during 
cytokinesis (North et a l, 2003). Furthermore, the cdcl4B phosphatase released in late M- 
phase, may act upstream of Sirt2 by indirectly targeting it for turnover by the 26S 
proteosome (Dryden et a l, 2003). This phosphatase would therefore inhibit the Sirt2- 
mediated delay in cell-cycle progression, thereby allowing cell-cycle progression. The
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cdcl4B protein and its interaction with Sirt2, mirror that of its cdcl4 yeast orthologue 
and its interaction with the Sir2-containing RENT complex (Shou et al., 1999, Straight et 
al., 1999). As with yeast Sir2, Sirt2 may participate in a late mitotic check-point to ensure 
correct chromosome segregation during cytokinesis (Figure 1.6).
Figure 1.6 Sirtuin 2 mediated cell-cycle regulation. This figure shows the putative role 
of the Sirt2 protein in cell-cycle regulation.
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As well as controlling mitotic exit, by modulating microtubule dynamics, Sirt2 may also 
control intracellular transport, motility and cell storage. Sirt2 has also been shown to 
interact with the homeobox transcription factor, suggesting a role for it in mammalian 
development (Bae et a l, 2004). Finally, nucleo-cytoplasmic shuttling of Sirt2 also occurs
30
in response to ionising radiation suggesting a possible role for it in the DNA damage 
response (Inoue et a l, 2006)
1,3.3 Sirtuin 3
Sirtuin 3 (Sirt3) is a cytoplasmic protein that is imported into and activated within the 
mitochondrion (Schwer et al., 2002, Onyango et al., 2002). Sirt3 is then able to 
deacetylate and thereby activate the mitochondrial matrix protein, acetyl CoA synthetase 
2 (AceCS2) (Figure 1.7). The cell requires acetyl CoA as an intermediate for the Krebs’ 
cycle, as well as other metabolic processes, including lipogenesis. Although acetyl CoA 
is ordinarily produced via the enzymatic conversion of pyruvate, the production of acetyl 
CoA by AceCS2 is particularly high during ketogenic conditions such as prolonged 
fasting or diabetes.
Indeed, the abundance of AceCS2 within heart and skeletal muscle under ketogenic 
conditions, suggests that Sirt3 may play an important role in AceCS2 activation and 
acetyl CoA production (Fujino et a l, 2001). Substantiating this, high levels of SIRT3 
expression are found in metabolically active tissue such as muscle, liver, kidney and heart 
(Onyango et al., 2002).
In response to oxidative stress, there may be a decrease in Sirt3 activity. In these cases, 
oxidative damage would cause an opening of the mitochondrial membrane permeability 
transition pore (mMPTP) and result in NAD moving into the inter-membrane space
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where it would be rapidly hydrolysed by NADase. This fall in NAD levels would result 
in a concomitant fall in Sirt3 activity. In this manner, analogous to Sirtl, Sirt3 may also 
act as a sensor of the redox state of the cell, permitting the cell to regulate metabolism, 
DNA repair, cell-cycle control and ageing in response to oxidative stimuli (Shiels, 1999, 
Smith et al., 2000).
Figure 1.7 Interaction of sirtuins with acetyl CoA transferases. This figure represents 
a model for the interaction of Sirtl and Sirt3 with the acetyl CoA transferases, AceCSl 
and AceCS2. These sirtuins appear to activate these transferases and may result in 
changes in metabolism and energy utilisation [Figure taken from Hallows et al., (2006)].
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1.3.4 Sirtuins 4 — 6
Although little is Icnown about Sirtuins 4 — 6 (Sirt4-6), recent discoveries suggest that 
these sirtuins may also play a part in stress responses (Haigis et a l, 2006, Mostoslavsky 
et al., 2006). As with Sirt3, the gene products of Sirt4 and Sirt5 are localised to the 
mitochondrion. Sirt4 has NAD-dependent ADP-ribosyltransferase activity and has been 
reported to downregulate mitochondrial glutamate dehydrogenase within pancreatic (3 
cells (Haigis et a l, 2006). This effect of Sirt4 may be inhibited by CR, perhaps as a result 
of alterations in the NAD/NADH ratio. The resultant reduction in glutamate 
dehydrogenase represses glucose and amino acid-induced insulin secretion. This activity 
is in contrast to that of Sirtl, which increases insulin secretion (Moynihan et a l,  2005). 
Sirtl-mediated repression of UCP-2 is alleviated by acute starvation, and that of Sirt4 on 
glutamate dehydrogenase, alleviated by chronic CR (Haigis et a l, 2006). These may 
reflect sirtuin regulation of insulin in response to varying types of nutritional stress.
Sirt6 also has ADP-ribosyltransferase activity (Liszt et a l, 2005) and has been shown to 
display nuclear localization, associating with heterochromatic regions that include 
centromeres and telomeres (Michishita et a l, 2005). Sirt6 has recently been shown to 
play an integral role in DNA repair and the maintenance of genomic stability in cells 
(Mostoslavsky et a l, 2006). The loss of SIRT6 expression, results in a fall in Base 
Excision Repair (BER). In transgenic mice deficient in SIRT6, this manifests in the 
development of a progeroid phenotype, characterised by loss of subcutaneous fat, 
lordokyphosis and severe metabolic defects (Mostoslavsky et a l, 2006). This observation
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is congruent with the MTR hypothesis linking sirtuins, telomere maintenance, DNA 
repair, metabolism and ageing (Shiels and Davies, 2003).
1.3.5 Sirtuin 7
Sirtuin 7 (Sii't7) maps to chromosome 17q25.3, a region frequently affected by 
chromosomal alterations in acute leukaemias and lymphomas. As with Sirt6, Sirt7 also 
displays nuclear localisation, but specifically associates with nucleolar rDNA (Ford et al., 
2006, Michishita et al., 2005). Here, Sirt7 interacts with and increases the transcription of 
RNA polymerase I (Pol I). Decreased Sirt7 activity reduces cell proliferation and triggers 
apoptosis and increased Sirt7 expression encourages cell growth and prevent apoptosis 
(Ford et a l, 2006).
1,3.5.1 Growth and proliferation
As with their yeast counterparts, mammalian cells also contain around one hundred 
copies of the rDNA gene that encodes rRNA. The rate at which these genes are 
transcribed by Pol I, matches the cell’s metabolic activity and demand for ribosomes. In 
response to changes in the cellular environment, rRNA transcription determines the 
potential for cell growth and proliferation (Shiels and Davies, 2003, Shiels, 1999). 
Interestingly, unlike Sirt7, Sirtl has been shown to repress Pol I transcription by 
deacetylating the TAF168 protein in mice (Muth etal., 2001).
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1.4 Sirtuins, ageing and cancer
The discovery that, in S. cerevisiae, lifespan extension in response to CR is Sir2- 
dependent, raises the possibility that sirtuins may have an analogous role in humans. 
Indeed, the consumption of red wine, that contains the potent Sirtl activator, resveratrol, 
is associated with longevity in humans (Howitz et a i, 2003) and may explain the 
‘Mediterranean paradox’ of why ageing-related diseases such as atherosclerotic arterial 
disease are less common in this population,.
In yeast, Sir2 mediates lifespan extension by linking mitochondrial energy production, 
protein synthesis and telomere maintenance. It is hypothesised that, like yeast Sir2, 
human sirtuins may similarly link the functions of the mitochondrion, telomere nucleo- 
protein complex and ribosomal machinery (the MTR) (Figure 1.8).
Telomere complex
Ribosome biogenesis Mitochondrion
Figure 1.8 The MTR. The interacting components of the MTR.
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Sirtl may do this by interacting with apoptotic factors to prevent DNA and telomeric 
damage, Sirt3 by altering energy production in response to the cell’s redox state and Sirt7 
by controlling ribosomal transcription and consequently protein synthesis. Furthermore, 
Sirt2 is involved in cell-cycle regulation and Sirt6 in DNA damage repair (Figure 1.9). 
This is a simplistic model, as Sirtl also acts in the cytoplasm and mitochondria and Sirtl 
in the nucleus.
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Figure 1.9 Sirtuins and the MTR. This figure shows the areas where sirtuins are 
thought to function within the cell, in particular, at the telomere, mitochondria and 
ribosomal DNA, to protect against cell stress and damage.
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Sirtuin activity at the MTR, allows the cell to regulate telomeric damage, oxidant load 
and protein biosynthesis. An imbalance in any one of these components would have a 
knock on effect on the others. For example, the accumulation of damage over a cell’s 
lifespan may be associated with accumulating DNA damage and telomere shortening, as 
well as inefficiency in mitochondrial fuel utilisation, energy production and decreased 
protein biosynthesis.
Sirtuin activity at each of these sites may counteract the accumulation of changes 
associated with the development of biological ageing. Indeed, accelerated ageing is 
linked with the development of a number of pathologies, and may be associated with 
aberrant sirtuin expression at any of these sites (Shiels and Davies, 2003). It is also 
established that factors that promote longevity result in a predisposition to cancer 
(Campisi, 2000). Aberrant sirtuin activity may, therefore, contribute to the pathogenesis 
of cancer.
The roles of sirtuins in preventing apoptosis in response to DNA damage (Luo et al., 
2001, Vaziri et al., 2001, Yeung et al., 2004), regulating the cell-cycle in response to 
chromosomal abnormalities (Dryden et al., 2003, North et al., 2003), controlling rRNA 
transcription (Ford et a l, 2006) and participating in DNA damage repair (Mostoslavsky 
et a l, 2006), provide areas where aberrant sirtuin activity may contribute to cancer 
pathogenesis. Indeed, increased SIRTl expression is a feature of a number of 
malignancies (Lim, 2006b, Kuzmichev et al., 2005, Chen et a l, 2005, Yeung et al., 2004,
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Bradbury et al., 2005), decreased SIRT2 expression a feature of gliomas (Hiratsiika et a l, 
2003) and gastric cancer (Inoue et al., 2006), and increased SIRT7 expression a feature of 
thyroid cancer (Frye, 2002, de Nigris et al., 2002).
The transcriptional analysis of sirtuin expression is, therefore, useful for the study of both 
biological ageing and cancer. In the proceeding chapters we will explore how sirtuin 
biology contributes to senescence, tumorogenesis as well as the cell damage response in 
breast cancer.
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1,5 Aims
The aim of this thesis was to study breast cancer as an aberration of normal biological 
ageing, with respect to sirtuin expression. Specifically, it sought to determine the role of 
sirtuins, that link components of the MTR, in mammary epithelial cell senescence as well 
as in the pathogenesis and progression of breast cancer. It also sought to determine the 
relationship between common therapies used for the treatment of breast cancer, namely 
radiotherapy and chemotherapy, and sirtuin expression.
In order to do this, transcriptional studies of sirtuin expression were performed to:
1. Determine the relationship between sirtuin expression in primary mammary 
epithelial cells as they age.
2. Investigate sirtuin expression in malignant and non-malignant breast tissue 
biopsies.
3. Determine the relationship between both ionising radiation and paclitaxel 
chemotherapy and sirtuin expression.
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Chapter 2 
Materials and Methods
40
2.1 Materials
Ambion. UK 
DNA"free Kit
Biosource UK Ltd. UK 
Taqman primer/probe sets
Bristol-Myers Squibb. USA 
Paclitaxel (6mg/ml)
Clontech. UK
Apoalert DNA Fragmentation Assay Kit
Eurogentech. UK 
Taqman mastermix
Inviti’ogen. UK
Superscript first-strand synthesis system for RT-FCR
GE Healthcare. UK 
X-Ray films
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Invitrogen, UK 
TRIzoI reagent
Superscript II reverse transcription system
Nalge Nunc International Fisher Scientific. UK 
Labtek II chamber slide system
Applied Biosvstems. UK 
MicroAmp optical 96-well PCR plate 
MicroAmp optical cap strips
Other chemicals used were supplied from Sigma Chemical Company Ltd, UK unless 
otherwise stated.
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2.2 Cell lines
The following cell lines were used in this study (Table 2.1). The MCF~12A cells were 
gifts from Dr Susan Jamieson (Department of Pathology, Western Infirmary, University 
of Glasgow) and MCF-7 cells from Dr Robert Mairs (Department of Radiation Oncology, 
University of Glasgow).
Table 2.1 Cell lines used in the in vitro studies.
Cell line Organism Tissue Characteristics Source
HMEC Human Mammaiy 
epithelial cells
Primary Clonetics, Cambrex 
Bioscience, UK
MCF-12A Human Mammaiy 
epithelial cells
Immortalized
non-tumorogenic ECACC, UK
MDA-MB-231 Human Mammary 
epithelial cells
Immortalized 
tumorogenic 
mutant p53
ECACC, UK
MCF-7 Human Mammaiy 
epithelial cells
Immortalized 
tumorogenic 
wild type p53
ECACC, UK
43
2.2.1 Growth conditions
The primaiy human mammaiy epithelial cells (HMEC) were grown in mammaiy 
epithelial cell growth medium supplemented with bovine pituitary extract (BPE), 20ng/ml 
epidermal growth factor, insulin and 500ng/ml hydrocortisone.
The MCF-12A cells were grown in a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium and Ham’s F 12 medium, supplemented with 5% foetal calf serum, 20ng/ml 
epidermal growth factor, lOOng/ml cholera toxin, 0.01 mg/ml bovine insulin and 
500ng/ml hydrocortisone.
The MCF-7 cells were grown in RPMI medium supplemented with 10% foetal calf 
serum.
The MDA-MB-231 cells were grown in Leibovitz’s L-15 medium with 2mM L- 
glutamine supplemented with 10% foetal calf serum.
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2.3 Breast biopsies
Archival breast biopsies stored in liquid nitrogen and held by the Department of Surgery, 
Western Infirmary, Glasgow, were used for the biopsy study. These biopsies came from 
patients with potentially curable, invasive ductal adenocarcinomas who had given 
permission for the storage and future analysis of samples of tissue. All patients had 
surgery with a curative intent (mastectomy or breast consei-vation surgery, and level II 
axillary clearance) performed by a single operator between 1996 and 2000. The 
pathological characteristics of each group were selected to include equal distribution by 
nodal status (12 lymph node positive and 12 lymph node negative), and tumour grade. A 
total of 24 breast cancer samples were chosen and matched with 21 ‘normal’, 
histologically non-malignant breast tissue biopsies fi’om the breasts of cancer patients.
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2.4 Extraction of total RNA
The TRIzol method of total RNA extraction was used for total RNA extraction from cell 
lines and breast biopsy tissue. Cells grown in tissue culture flasks were mixed with 1ml 
of TRIzol reagent. 0.2mls of chloroform was added for each 1ml of TRIzol reagent used. 
The tubes were left at room temperature for 3 minutes. Samples were then centrifuged at 
12,000G for 15 minutes at 4°C. The resultant aqueous phase was carefully removed, and 
transferred to an epindorf containing 0.5ml isopropanol, for each 1ml of TRIzol reagent 
used. The tubes were mixed and incubated at room temperature for 10 minutes, to allow 
RNA to precipitate before being centrifuged at 12,000G for 10 minutes at 4°C to pellet 
the RNA. The supernatant was removed and the RNA pellet washed by adding 1ml of 
75% ethanol, vortexing and centrifuging at 7,500G for 5mins at 4°C. The RNA pellet was 
air-dried and resuspended in DEPC-treated water. Samples were heated for 10 minutes at 
60°C before being put on ice. For the extraction of total RNA form biopsy tissue, breast 
glandular tissue was carefully dissected free from surrounding fatty tissue. 1ml of TRIzol 
was added per 50mg of tissue. Tissue was then homogenised using a mechanical tissue 
homogenize!' at 0°C. The resultant homogenate was then processed as above.
The quality of the RNA was tested by running 500ng of the sample on a 0.5% agarose gel 
containing 0.5p.g/ml Ethidium bromide and visualising under UV light. The RNA 
concentration and purity was determined by measuring absorbance of the sample at 
260nm using a GeneQuant capillai'y spectrophotometer (Pharmacia Biotech). Samples 
were stored at ~80°C.
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2.5 Taqm an Real-time PCR
Taqman real-time PCR is a cDNA-specific 5’ nuclease assay for quantitatively detecting 
PCR products using a non-extendable oligonucleotide hybridisation probe. The probe is 
labelled with a reporter fluorescein dye, 6-carboxy-fluorescein (FAM), at the 5’ end and a 
quencher fluorescent dye, 6-carboxy-tetramethyl-rhodamine (TAMRA), at the 3’ end. 
When the probe is intact, the reporter dye emission is quenched due to the physical 
proximity of the reporter and quencher fluorescent dyes. During the extension phase of 
the PCR cycle, the nucleolytic activity of the Taq DNA polymerase cleaves the 
hybridisation probe and releases the reporter dye from the probe (Figure 2.1). With each 
cycle of PCR amplification there is an increase in fluorescence emission which is 
monitored in real-time using the ABI Prism 7700 sequence detector (Heid et a l,  1996).
The sequence detector is a combination thermal cycler, laser and detection software 
system that automates 5’ nuclease-based detection and quantitation of nucleic acid
sequences. A computer algorithm compares the amount of reporter dye emission (Rn+)
with the quenching dye emission (Rn-) during the PCR amplification, generating a AR^
value. The AR^ value reflects the amount of hybridised probe that has been degraded. The
algorithm fits an exponential function to the mean AR^ values of the last three data points 
for every PCR extension cycle, generating an amplification plot.
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Taqman PCR was performed for specific genes and simultaneously performed using 
primer/probe sets for either hypoxanthine phosphoribosyltransferase (HPRT) or the 18S 
ribosomal subunit, housekeeping genes used as internal references. The amplification of 
the endogenous control allowed us to standardise the amount of RNA in each reaction.
A threshold was set at a point where this amplification appeared linear. The resultant 
threshold cycle number (Ct) for both of these genes was recorded for each sample. This 
allowed the expression of the gene of interest to be normalized to the endogenous 
housekeeping gene. This was performed by calculating the ACt sample by subtracting the 
Ct value of the endogenous housekeeping gene from the Ct vale of the gene of interest
(ACt Sample “  Ct Gene of interest ~ Ct Housekeeping gene)
The comparative Ct method, also known as the method, was used for calculating 
the relative gene expression. This involved comparing the ACt values o f the samples with 
a control or calibrator, such as RNA from a non-treated sample or normal tissue. This 
involves calculating the AACt, by subtracting ACt calibrator from the ACt sample-
For the AACt calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference housekeeping gene must be approximately equal. This can be 
established by looking at how ACt sample varies with template dilution. If the gradient of 
cDNA dilution versus ACt sample is close to zero, it implies that the amplification 
efficiencies of the target and housekeeping genes are similar (Figure 2.2 and 2.3).
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Figure 2.1 Taqman PCR. This is a diagrammatic representation of the steps involved in 
the real-time Taqman PCR reaction [Illustration adapted from Applied Biosystems 
Taqman Manual]
1. The primers and probe anneal to the cDNA transcript. There is no fluorescence 
because the reporter dye emission is quenched.
2. The primers are extended during the extension phase of the PCR cycle.
3. The 5’-3’ exonuclease activity of the DNA polymerase cleaves the hybridised 
probe and releases the reporter dye emission resulting in an increase in reporter 
fluorescent dye emission.
4. The primers continue to be extended until polymerisation of the amplicon is 
complete.
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2.5.1 DNase treatment
DNAse treatment was performed using the commercially available DNA-Free Kit 
(Ambion). RNA was added to a tube containing 2-3 units of DNase I and 0.1 volume of 
lOx DNase I Reaction Buffer. The contents of the tube were mixed gently and incubated 
for 30 minutes at 37°C. The DNase I was then inactivated by adding 0.1 volume of 
DNase Inactivation Reagent. The mixture was incubated for 2 minutes at room 
temperature. The solution was then centrifuged for 1 minute to pellet the DNase 
Inactivation Reagent. The supernatant contained the DNase-treated RNA.
2.5.2 cDNA Synthesis
Two micro grams of RNA was then reverse transcribed into cDNA using the Superscript 
First-strand Synthesis System for reverse transcriptase PCR (Invitrogen) 
recommendations. This part of the study was performed in duplicate with each sample 
being treated with or without the reverse transcriptase (RT) enzyme. Random hexamer 
based transcription was performed for the breast biopsy studies and oligonucleotide 
(oligodTs) based transcription for experiments using mammary cell lines. Random 
hexamer-based transcription has been shown to generate a more normalised cDNA pool 
from sources that may contain partially degraded RNA (Schwabe et a l, 2000).
For the hexamer-based RT reaction Ipl o f lOmM dNTP mix and 2p l hexamers were 
added for every 2)Lig of RNA to be reverse transcribed. The total volume was made up to
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10|l l 1 using DEPC-treated H2O2. The mixture was then incubated at 65°C for 5 minutes 
before being placed on ice. 2|l i 1 of lOx RT Buffer, 4|ul o f 25mM MgCl2, 2ju,l of O.IM DTT 
and finally Ipl of the RNase inhibitor, RnaseOUT, were then added, bringing the total 
volume up to 19pl. This mixture was gently mixed by brief centrifugation before being 
incubated at 20°C for 2 minutes. Ipl of the reverse transcriptase enzyme, Superscript II, 
was then added, but only to those samples to be reverse transcribed and not to the no-RT, 
negative controls. The total mixture was then incubated at 25°C for 10 minutes, at 42°C 
for 50 minutes, terminated at 75°C for 15 minutes and finally chilled on ice for 5 minutes. 
Finally, the reactants were treated with I p l o f  RNAse at 37°C for 20 minutes. The 
specimens were then stored at -20°C.
For the oligo dT-based RT reaction Ipl of lOmM dNTP mix and Ijul oligo dTs was added 
for every 2jLig of RNA to be reverse transcribed. The total volume was made up to lOpl 
using DEPC-treated H2O2. The mixture was then incubated at 60°C for 5 minutes before 
being placed on ice. 2pl of lOx RT Buffer, 4|l i 1 of 25mM MgCl2, 2|ul of O.IM DTT and 
finally Ipl of the RNase inhibitor, RnaseOUT, were then added, bringing the total 
volume up to 19pl. This mixture was gently mixed by brief centrifugation before being 
incubated at 42°C. Ijul of the reverse transcriptase enzyme, Superscript II, was then 
added, but only to those samples to be reverse transcribed and not to the -RT, negative 
controls. The total mixture was then incubated at 42°C for 50 minutes, terminated at 70°C 
for 15 minutes and finally chilled on ice for 5 minutes. Finally, the reactants were treated 
with Ipl of RNAse at 37°C for 20 minutes. The specimens were then stored at -20°C.
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2.5.3 Taqman PCR
Taqman PCR was carried out on the cDNA samples using the ABl Prism 7700 sequence 
detector (Applied Bio systems) in a 25pl reaction. The mixture consisted of lO-lOOng of 
cDNA, 300nM of each primer, 200nM Taqman probe, 12.5j l i 1 of Taqman Universal PCR 
Master Mix (Eurogentech, UK) and H2O2. Cycle conditions were 50°C for 2 minutes, 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute.
2.5.4 Design of Taqman primers and probes
Taqman primer and probe sequences for all genes (Table 2.2) were designed de novo 
from sequences in the Genebank database using Primer Express software. All 
primer/probe sets were designed such that at least one of the oligonucleotides crossed an 
intro/exon boundaiy.
All primer/probe sets were subsequently tested by blasting and amplifying the cDNA. 
This was to ensure that the primers and probe did not bind other sequences and that 
primer dimers were not formed.
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2.5.5 Validation studies
For comparative PCR to be valid, the efficiencies of the target amplification and the 
amplification of the reference gene must be approximately equal. To check this, an initial 
experiment was set up using dilutions of cDNA as follows.
Table 2.3 Concentrations of cDNA template amplified for validation studies on each 
prim er/probe set.
Target gene Reference gene
500ng lOOng 20ng 4ng 800pg 500ng lOOng 20ng 4ng 800pg
Each reaction was run in duplicate. The PCR reaction mix for Taqman validation (25pl) 
consisted of Ix Taqman Universal PCR Master Mix, 300nM of both forward and reverse 
primers, 200nM Taqman probe and 800pg to 500ng of mammary epithelial cell line 
cDNA and breast biopsy cDNA (Table 2.3). The cycling conditions were as described in 
2.5.3.
The ACt for each gene primer/probe set, i.e. values of Ct Gene of interest -  c t  Housekeeping gene 
was relatively constant for SIRT2,3, 7 and p21, using HPRT as the internal reference gene 
(Figure 2.3). Likewise the ACt was relatively constant for SIRT2, SIRT3 and SIRT7, using 
18S as the internal reference gene (Figure 2.4). The efficiencies of the target 
amplification of SIRTl and that of both HPRT and 18S was only equal between a 
template concentration of 0.8 and 20ng. lOng o f template were, therefore, used for the
54
Taqman experiments. No amplification was seen in the wells containing the ‘no RT’ 
controls, or in the wells lacking any template.
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Figure 2.2 Relative efficiencies of SIRTl,2,3,7 and p21 with reference to HPRT. 
These figures show how the ACt for SIRTl,2,3,7 and p2I  varies with logio [template 
concentration] with reference to the HPRT housekeeping gene.
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Figure 2.3 Relative efficiencies of SIRTl,2,3 and 7 with reference to 18S. These 
figures show how the ACt for SIRTl,2,3 and 7 varies with logio [template concentration] 
with reference to the I8S  housekeeping gene.
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2.5.6 Primer and probe optimisation
The purpose of this procedure was to ensure that all primer/probe sets gave amplification 
that was both detectable, and shown to increase exponentially with each PCR cycle. Each 
reaction was, again, run in duplicate. The PCR reaction mix for primer/probe 
optimization (25|ul) consisted of Ix Taqman Universal PCR Master Mix, 300nM of both 
forward and reverse primers, 200nM Taqman probe and lOOng of mammary epithelial 
cell line cDNA. The cycling conditions were as described in 2.5.3.
These primer/probe concentrations provided satisfactoiy results for all but the original 
SIRT7 primer/probe set designed. Despite running an optimisation plate (Table 2.4) with 
varying concentrations of both forward and reverse primers, no amplification was seen. 
SIRT7 was therefore re-designed and this time the new primer/probe set worked.
Table 2.4 Combinations of forward and reverse primers for primer/probe set 
optimisation.
50fwd/50rev 50fwd/300rev 50fwd/900rev
300fwd/50rev 300fwd/300rev 300fwd/900rev
900fwd/50rev 900fwd/300rev 900fwd/900rev
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2.6 TUNEL assay
Apoptosis was detected using the Apoalert DNA Fragmentation Assay Kit (Clontech). 
This assay detects DNA strand breaks by terminal deoxynucleotidyl transferase (TdT)- 
mediated dUTP nick-end labelling (TUNEL), TdT catalyses the incorporation of 
fluorescein-dUTP at the free 3’-hydroxyl ends of fragmented DNA. The fluorescein- 
labelled DNA can then be detected using fluorescence microscopy.
2.6.1 Sample preparation
Apoptosis was detected in cells grown on Labtek II Chamber Slides (Nalge Nunc). 
Following treatment slides were washed twice in PBS. Cells were then fixed by 
incubating slides for 25 minutes in 4% formaldehyde/PBS at 4°C. Slides were then 
immersed in PBS for 5 minutes and again washed twice in PBS. Cells were then 
permeabilised by incubating cells for 5 minutes in pre-chi lied 0.2% Triton X-100/PBS.
A DNase-treated positive control was also prepared at this stage. This slide was incubated 
in lOOpl of DNase 1 buffer at room temperature. Following this, the slide was incubated 
in lOOpl of DNase 1 buffer containing 0.5-lpg/ml DNase for 10 minutes. The slide was 
then washed 3-4 times in H2O before being treated with the other samples as follows.
Slides were then incubated for a further 5 minutes in PBS at room temperature. This step 
was repeated. Slides were now ready for the tailing reaction.
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2.6.2 Tailing reaction
The tailing reaction describes the incorporation of fluorescein-dUTP to the free 3’- 
hydroxyl tails of fragmented DNA.
lOOpl of equilibration buffer was then added to the slides for 10 minutes at room 
temperature. TdT incubation buffer was then prepared for all o f the samples. This 
consisted of;
Equilibration buffer 45pl
Nucleotide mix 5pl
TdT enzyme Ipl
A TdT-minus, negative control was also prepared. Deionised H2O was substituted in 
place of the TdT. 50jiil of TdT incubation buffer was then placed on the cells. Coverslips 
were added and the Samples were then placed for 60 minutes in a dark, humidified 37°C 
incubator. The tailing reaction was terminated by immersing the slides in 2xSSC at room 
temperature for 15 minutes. Cells were then washed by immersing in PBS at room 
temperature for 5 minutes. This was repeated twice. Cells were then stained with 
propidium iodide(PI)/PBS for 5-10 minutes at room temperature. Cells were then washed 
by incubating with deionised H2O at room temperature for 5 minutes. This was repeated 
twice. Anti-fade solution was then added and slides were covered with glass coverslips.
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2.6.3 Fluorescence microscopy
The stained specimen was then observed in a triple band-pass filter using the Zeiss 
Axioplan 2, epifluorescence microscope. Apoptotic cells exhibited a strong, nuclear green 
fluorescence using a standard fluorescein filter set (520±20nm). All cells stained with PI 
exhibited strong red cytoplasmic fluorescence when viewed at >620nm (Figure 2,6). To 
determine the degree of apoptosis, two experiments in total were performed, and the 
percentage of cells exhibiting apoptosis in a field of approximately 100 cells was 
recorded.
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2.7 Senescence studies
2.7.1 Mammary cell line studies
Three different types of mammary epithelial cell lines were used in the investigations 
described in this thesis. These cell lines were a primary human mammary epithelial cell 
line (HMEC), an immortalized non-tumorogenic human mammary cell line (MCF-12A) 
and immortalized tumorogenic human mammary cell lines (MCF-7 and MDA-MB-231). 
Cells were seeded and collected at successive passages with three population doublings 
between each passage. The number of population doublings were calculated by growing 
cells to sub-confluence before splitting them in a 1 in 8 manner. RNA was extracted from 
these cells before being subject to Taqman analyses for established senescent associated 
genes (SAGs) including Sirtuins 1,2,3 and 7.
2.7.2 Senescence-associated p galactosidase assay
Cells to be assayed were washed twice in PBS then treated with 1ml of Ix fixation 
solution (2% formaldehyde/0.2% gluteraldehyde) at room temperature for 10 minutes. 
Cells were then washed twice with PBS.
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Cells were then stained using the staining solution which was constituted as follows:
Volume per well Final concentration (per Imll
50 pi X-Gal (20mg/ml)
12.5pl Potassium Ferrocyanide (400mM)
12.5pl Potassium Ferrocyanide (400mM) 
lOpl MgCL (200mM) 
lOOplNaCl in Ix PBS (1.5M)
Citric acid/ sodium phosphate pH 6.0 in Ix PBS
Img
5mM
5mM
2mM
150mM
40mM
1ml of staining solution was then added to each well and cells were incubated at 37°C 
(without CO2) for 8-12 hours. 100 cells were then examined under a light microscope for 
SA-p-gal staining. A positive control at pH 4.0 was also analysed.
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2.8 Cancer therapy experiments
2.8.1 Cellular irradiation
The MDA-MB-231 and MCF-7 cells respectively were grown in 25cm^ tissue culture 
flasks and glass chamber slides (Labtek) to 70% confluence and then subjected to varying 
doses of radiation. Cellular irradiation was performed using a *^ °Co source with a 0.8-cm 
Perspex ‘build up’ to ensure maximum energy deposition. The dose rate was 
approximately 0.5Grays/min, and the treatment dose ranged from 2 to 10 Grays.
All experiments were performed in duplicate. Cells were harvested at two distinct time 
points after irradiation, 24 hours and 48 hours prior to further investigations.
2.8.2 Taxol treatment
The MCF-7 cells were grown in 25 cm^ tissue culture flasks to 70% confluence and then 
subjected to different doses of paclitaxel treatment (lOnM to lOOpM). Cells were 
incubated for 24 hours in the presence of the drug before being harvested.
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2,9 Statistical analyses
Analysis of individual genes expression between each of biopsy groups (i.e. non- 
malignant, lymph node negative and lymph node positive breast biopsies) was performed 
using an analysis of variance (ANOVA). Post-hoc comparisons were then performed 
using the independent student’s t-test.
Linear regression analyses were performed to determine if any relationship existed 
between passage in replicatively ageing mammary epithelial cells and sirtuin expression 
as well as between irradiation and paclitaxel treatment and sirtuin expression. Linear 
regression analyses were also performed to determine whether there was an association 
between SA-P-Gal staining and replicative age. Both and p-values were calculated to 
show the ‘goodness of fit’ of the models as well as their statistical significance.
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Chapter 3
Investigations into Sirtuin Expression in 
Mammary Epithelial Cells In Vitro
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3.1 Introduction
Cells explanted from living tissue into culture undergo a finite number of divisions before 
entering growth arrest (Hayflick and Moorhead, 1961). This phenomenon is known as 
replicative senescence (RS) and has been likened to a tumour suppressor mechanism, as it 
must be overcome for cells to achieve immortalisation (Campisi, 2000). Sirtuins are 
implicated in preventing replicative senescence in a number of cells (Langley et ah, 2002, 
Lim, 2006a, Kim et ah, 2004) and may perform this function by functioning within the 
MTR. Specifically, they may help stabilise telomeres and repair DNA damage, improve 
the efficiency of energy production and fuel utilisation and regulate the rate of protein 
biosynthesis (Shiels and Davies, 2003). Understanding the changes that occur in sirtuin 
expression within ageing mammary epithelial cells may help in understanding breast 
tumorogenesis. Here follows a review of senescence, as well as the role sirtuins may play 
in this process.
3.1.1 Replicative senescence
Replicative senescence is characterised by an irreversible arrest of cell proliferation, as 
well as altered cell function. Various models of senescence exist although these are not 
mutually exclusive. The most celebrated model of seneseence is the telomere-based 
model.
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3.1.2 Telomere model of senescence
The telomere model of RS predicts senescence to occur once telomeres reach a critically 
shortened length. Telomeres are specialised nucleoprotein structures found at the end of 
eukaryotic chromosomes and consist of tandemly repeated TTAGGG motif bound by a 
variety of proteins. Telomeres have numerous roles, including the maintenance of 
chromosome structure and integrity. As cells divide, DNA polymerases are incapable of 
completing replication at telomeric ends, with the result that telomeres progressively 
shorten, culminating in growth arrest once they reach a critically shortened length 
(Olovnikov, 1973). This model is overly simplistic, as it has been since shown that it is 
altered telomere state and not telomere length that results in senescence (Karlseder et a/.,
2002). Telomeric alterations may also result in the expression of sub-telomeric genes that 
contribute to the senescent phenotype (Baur et al., 2001). Expression of the telomerase 
enzyme maintains telomere lengths and can result in immortalisation in certain cell types. 
Telomerase has been shown to be up-regulated in over 80% of tumours, with the 
remainder possibly employing a mechanism known as alternate lengthening of telomeres 
(ALT) to maintain their telomere length (Stewart and Weinberg, 2000).
3.1.3 Stress or Aberrant Signalling Induced Senescence
Stress or Aberrant Signalling Induced Senescence (STASIS) is the name given to the 
senescence state induced by cellular damage (Wright and Shay, 2002). As cells age they 
accumulate damage at the nuclear, mitochondrial and cytoplasmic level (Shiels and
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Davies, 2003). Once this damage reaches a critical limit, cells undergo senescence. 
Independent of primary telomeric changes, this senescent state can be induced in vitro by 
the activation of oncogenes (Serrano et al., 1997), exposure to sub-cytotoxic stressing 
agents (Chen et a l, 1995), agents that perturb chromatin structure (resulting in a loss of 
silencing) (Ogiyzko et a l, 1996) as well as by primary changes in either the p53 or the 
pRb pathways (McConnell et a l, 1998). The accumulation of damaged, dysfunctional 
mitochondria resulting in inefficiencies in fuel utilisation, reduced energy availability, 
impaired cellular function and eventually cell death are also associated with senescence, 
disease and ageing (Linnane et al., 1989, Brunk and Terman, 2002).
3.1.4 Cell-cycle checkpoints and senescence
The cell-cycle is normally governed by interactions between cyclins and cyclin- 
dependent kinase (cdk) proteins which form complexes that regulate the cell-cycle at 
various checkpoints. Phosphorylation and thereby, inactivation, of the retinoblastoma 
protein, pRb, by cyclin-cdk protein complexes, mediates the release of E2F transcription 
factors that interact with histone acetylases. These open chiomatin structure and promote 
the expression of genes required for cell-cycle progression.
Telomere shortening, secondary to replicative ageing, results in the induetion of p53 and 
may lead to elevation of the cdk inhibitor, p21^^^\ The p21^^^  ^ protein prevents 
phosphorylation of pRb, thereby repressing gene expression and resulting in cell-cycle 
arrest. Although transcription is primarily activated by p53, p53-independent
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pathways also exist. Following changes in p2 l‘"^ ^^  expression, levels of the cdk-inhibitor 
pl6iNK4a also increase (Sklavounou et a l, 2006). These cdk inhibitors bind cdk proteins, 
thereby, preventing their interaction with cyclins (Sherr and Roberts, 1999). Elevated 
levels of p i 6^^"^  ^are thought to be required for maintenance of the senescent state (Stein 
et a l, 1999).
3.1.5 Seneseence and eaneer
The discovery that many of the stressors that precipitate senescence are oncogenic, has 
led to the understanding that senescence can be thought of as a mechanism by which 
higher organisms suppress the proliferation of cells at risk of malignant transformation 
(Campisi, 2000, Shay and Roninson, 2004). Indeed, many of the inducers and mediators 
of senescence are aberrant in cancer cells. The study of senescence therefore not only 
helps in understanding ageing and degenerative disease, but also in understanding 
tumorogenesis.
3.1.6 Senescence-associated changes
Senescent cells are not only growth arrested and unresponsive to mitogenic stimuli, but 
also display an altered function (Joosten et al., 2003, Campisi, 2000). These senescence- 
associated changes are both morphological, biochemical and molecular. Morphological 
changes include the acquisition of flattened shape and altered size (Bayreuther et a i, 
1988) and biochemical changes, the increased expression of senescent-associated
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biomarkers such as senescence-associated-p-galactosidase (Dimri et a l, 1995). 
Established molecular changes of senescence, include the overexpression of cdk 
inhibitors such as and (Stein and Dulic, 1998, Sklavounou et a l, 2006).
These proteins are implicated in inhibiting cyclin and cdk-mediated cell-cycle 
progression. The p21^^^  ^ protein progressively accumulates in ageing cells, reaching a 
peak at the early stages of senescence, before declining. In contrast, levels of p i6^^"^  ^
increase in the terminal stages of senescence and are, thereafter, maintained (McConnell 
et a l, 1998, Stein and Dulic, 1998).
3.1.7 Sirtuins and senescence
In S. cerevisiae, Sir2 is involved in the recombinational suppression of ERCs (Kaeberlein 
et a l, 1999), the repair o f DNA damage (Tsukamoto et a l, 1997) as well as the 
maintenance of telomeres (Grunstein, 1997, Aparicio et a l, 1991, Moretti et a l, 1994). 
Disruption of these Sir2-mediated functions can result in senescent-like growth arrest. 
Furthermore, the NAD-dependence of Sir2 activity links senescence with the cell’s 
ability to utilise fuel (Shiels, 1999). Indeed, in S. cerevisiae and the nematode, C. elegans, 
lifespan extension, secondaiy to caloric restriction, is linked to Sir2 activity, with 
absolute levels of Sir2 determining when senescence occurs (Lin et a l, 2000, Guarente 
and Kenyon, 2000).
Analogous to yeast Sir2, human siituins may link the mitochondrion, telomere nucleo­
protein complex and ribosome production (the MTR) with senescence (Shiels and
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Davies, 2003, Shiels, 1999). Sirtuins function within various components of the MTR 
and, perturbation of sirtuin activity at any one of these sites, may impact on global sirtuin 
activity and result in growth arrest and senescence.
Sirtl has been shown to be a negative regulator of p53 and has been suggested to play a 
part in the ability of stressed cells to repair damage and resist both apoptosis and 
senescence (Luo et al., 2001, Vaziri et al., 2001, Langley et al., 2002, Chua et al., 2005). 
Deacetylation of p53 by Sirtl, within pro-myelocytic leukaemia nuclear bodies, has been 
shown to antagonise p53 and cellular senescence (Langley et a l, 2002). Decreasing 
levels of SIRTl transcription and protein levels are also seen in ageing primary human 
fibroblasts and epithelial cells in culture (Michishita et al., 2005, Sklavounou et al., 
2006). Selective knockdown of the SIRTl gene using short interfering RNA (siRNA) 
causes senescence, in both non-malignant and malignant cells (Ota et a l, 2005). Sirtuin 
activators have also been implicated in the prolongation of lifespan and delaying 
senescence (Howitz et al., 2003, Wood et al., 2004). This is further substantiated by in 
vivo studies of Sirtl and senescence. With increasing donor age, decreased levels of Sirtl 
and increased levels of hyperacetylated p53 and p21^^^  ^ proteins are seen in human 
gingival fibroblasts (Kim et al., 2004, Araki et al., 2004). These observations collectively 
suggest that Sirtl may protect against senescence and absolute levels of Sirtl may 
determine when cells enter into this state.
Sirt2 participates in the regulation of the cell-eycle and functions to deacetylate a-tubu lin 
thereby arresting growth (Dryden et al., 2003, North et al., 2003). Acetylated a-tubulin is
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a key component of stable microtubules and is generated at the time of the cell-cycle by 
mammalian cells. These stabilised microtubules help coordinate cytokinesis and cell- 
cycle transition (Piel et a l, 2001). Microtubule dysfunction is associated with polyploidy 
and replicative senescence (Wagner et a l, 2001) and agents that cause microtubule 
stabilisation result in accelerated senescence (Klein et a l, 2005). Sirt2 may respond to 
chromosomal abnormalities that result from senescence, increasing mitotic arrest.
Sirt3 is localised and activated within the mitochondria. Siit3 activity is linked with the 
availability of fuel as well as with the oxidative state of the cell via its NAD-dependent 
enzymatic activity (Hallows et a l, 2006). In response to stresses such as chronic 
starvation, increased levels of Sirt3 and NAD promote acetyl Co A production from 
acetate to fuel the Krebs’ cycle. This increases the efficiency of fuel utilisation and 
energy production thereby decreasing the cell’s oxidant load and promoting longevity 
(Shiels and Davies, 2003). In contrast, acute oxidative stresses result in a fall in NAD 
levels and, therefore, Sirt3 activity and result in a decreased efficiency of fuel utilisation 
and energy production that may contribute to senescence and ageing. The role of the 
other mitochondrial sirtuins, Sirt4 and Sirt5, may be similar to Sirt3 in improving the 
utilisation of fuel in times of stress and promoting survival (Haigis et a l, 2006). In 
addition, as with Sirtl, the mitochondrial sirtuins may play a part in protecting against the 
accumulation of mitochondrial damage, a process that is also implicated in biological 
ageing and senescence (Brunk and Terman, 2002).
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Sirt6 has been shown to be involved in DNA base-excision repair, with absence of Sirt6 
resulting in a progeroid phenotype in transgenic mice (Mostoslavsky et ah, 2006). This 
suggests that Sirt6 helps prevent the accumulation of damage that results in cellular and 
subsequently physiological senescence.
As previously mentioned, Sir2 determines lifespan in S. cerevisiae by repressing the 
recombination formation of ERCs within rDNA at the nucleolus (Kaeberlein et ah, 1999, 
Guarente, 1997). Sirt7 is the only human sirtuin to localise to the nucleolus but, unlike 
yeast Sir2, has been shown to activate Pol I transcription at the rDNA, encouraging 
growth and proliferation (Ford et a l, 2006). However, analogous to the role of yeast Sir2, 
intrinsic Sirt7 levels may determine when a cell becomes senescent. This theoiy is 
supported by the observation that Sirt7 protein levels fall in both ageing human epithelial 
cells and fibroblast in vitro (Michishita et a l, 2005).
Furthermore, the redistribution of sirtuins from areas of silencing to areas of DNA 
damage over a cells lifespan may result in a gradual decline in sirtuin activity and fall in 
the integrity of silenced chromatin. In this way, decreased silencing may, with resultant 
genomic instability, may contribute to the senescent phenotype (Neumeister e ta l ,  2002). 
It is perhaps this loss of silencing that results in the gradual reactivation of the silenced 
mammalian X-chromosome with age (Surralles et a l, 1999).
Finally, rather than changes within the chromatin or altered telomeric state stimulating 
senescence, senescence-inducing signals may come from the loss of silencing and
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expression of sub-telomeric genes (Baur et a l, 2001). Over a cells life, the cumulative 
sirtuin reduction from telomeric regions may not only destabilise the telomeres and result 
in telomeric damage, but also result in the expression of sub-telomeric genes, that induce 
senescence (Shiels and Davies, 2003), Evidence to suggest this comes from studies that 
show altered SIRT3 expression to be associated with survival in the elderly (Rose et al.,
2003).
In summary, senescence may be regarded as a tumour suppressor mechanism that must 
be overcome for immortalisation. Furthermore, sirtuins within individual components of 
the MTR may be related to damage responses that contribute to biological ageing and 
senescence. Subsequently, perturbation of sirtuin activity may be associated with 
tumorogenesis. The study of sirtuin expression in normal replicative senescence is, 
therefore, of value in understanding cancer.
This thesis has sought to establish the transcriptional expression profile for individual 
sirtuins as a function of normal biological ageing, and to compare it with expression 
profiles in immortalised and cancer cells.
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3.1.8 Aims
In this part of the study, sirtuin gene expression was investigated in primary and 
immortalised mammary epithelial cells as a function of in vitro growth.
Individual questions addressed were;
1. How does sirtuin transcriptional expression alter in replicatively ageing mammary 
epithelial cells?
2. Are these changes associated with established molecular and biochemical markers 
of senescence?
3. How does this compare to sirtuin transcriptional expression profiles in 
immortalised mammary cell lines?
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3.2 Results
Sirtuin expression was measured in mammaiy epithelial cell lines as they underwent 
replicative ageing. These cell lines included a primary mammary epithelial cell line 
(HMEC), an established immortalised non-tumorogenic breast cell line (MCF-12A) and a 
tumorogenic breast cancer cell line (MCF-7). Gene expression was measured using 
Taqman real-time relative quantitative PCR and Senescence-associated p-galactosidase 
(Sen-p-gal) assays were performed.
3.2.1 Replicative senescence
Primaiy human mammary epithelial cells (HMEC) from a culture grown for seven 
population doublings (PD) were seeded and serially passaged. Cells grown to sub- 
confluence were split in a 1 in 8 manner ensuring that there were approximately three PD 
between each successive passage. After three passages, that is after nine PD, the HMEC 
stopped proliferating and displayed a senescent morphology. The acquisition of the 
senescent phenotype by the HMECs, with serial passage, was confirmed by a 
transcriptional analysis of the senescence-associated genes, and The
expression of both, and showed an increase with successive passage in
the HMEC, unlike that of the immortalised, non-tumorogenic MCF-12A cell line and 
immortalised, tumorogenic MCF-7 cell line (R^ = 0.933, p-0.002 and R  ^ = 0.944, 
p=0.001 respectively) (Table 3.1 and Figure 3.1). SIRTl and SIRT2 showed no obvious 
pattern of change in transcriptional expression in successively passaged cells, unlike 
SIRT3 and SIRT7, which showed a progressive increase in transcriptional expression with
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passage in the HMEC compared to the immortalised mammary cell lines (R^ = 0.825, 
p=0.012 and R^= 0.772, p=0.021 respectively) (Table 3.1 and Figure 3.2). Similarly, SA- 
(3-gal assays showed increased staining with successive passage in the HMEC, but not in 
the immortalised MCF-12A cell line (R^ = 0.969, p^O.OOO) (Figure 3.3).
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Table 3.1 Relationship between replicatively ageing mammary epithelial cells and 
sirtuin, p l6  and p21 expression. The table shows linear regression analyses for the 
relationship between replicative ageing and sirtuin, p l6  and p21 transcriptional 
expression in primary human mammary epithelial cells. values and p-values are 
displayed. *p<0.01, **p<0.05
HMEC ET p-value
P16 0.933 0.002*
P21 0.944 0.001*
SIRTl 0.222 0.346
SIRT2 0.212 0,358
SIRT3 0.825 0.012*
SIRT7 0.772 0.021**
79
Figure 3.1 Senescence-associated gene expression in proliferating human mammary
epithelial cells. Histograms shows mean p l6  and p21 gene expression in primary cell 
cultures (HME) and immortalised breast cell lines (MCF-I2A and MCF-7). Data is 
plotted as means ± s.d. (n=2)
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Figure 3.2 Sirtuin expression in proliferating human mammary epithelial cells.
Histograms shows mean SIRTl,2,3 and 7 gene expression in primary cell cultures (HME) 
and immortalised breast cell lines (MCF-12A and MCF-7). Data is plotted as means ± 
s.d. (n=2)
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Figure 3.3 Senescence-associated p-galactosidase staining in successively passaged 
hum an mammary epithelial cells. Histograms shows mean shows mean Senescent-P- 
galactosidase expression in successively passaged primary cell cultures (HME) and 
immortalised breast cell lines (MCF-12A). Data is plotted as mean ± s.e.m. (n=2)
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3.3 Discussion
Cellular senescence represents a mechanism by which an organism suppresses 
proliferation of cells at risk of malignant transformation (Campisi, 2000). Studying the 
transcriptional of human sirtuins in primary mammary epithelial cell ageing may, 
therefore, help us understand breast cancer pathogenesis from the perspective of 
biological ageing as a platform for disease.
3.3.1 Senescence-associated gene expression and SA-p-Galactosidase staining
The transcriptional expression o f p i  and p21^^^\ as well as, SA-p-Gal staining were
studied in replicatively ageing cells to determine whether these cells were displaying a 
replicative senescence state. Transcriptional expression of pl6^^^"^° and p21^^^^ and SA- 
p-Gal staining were noted to increase in serially passaged primary HMEC. The changes 
in p i expression observed confirm previous observations (Kim et a l,  2002). The 
lack of expression of plô^^^'^^ in either of the immortalised cell lines is predictable, as 
deletion of the cdk inhibitor, is a recognised step in the immortalisation of
mammary cancer cell lines (Musgrove et a l, 1995). Elevated levels of p21^^^^ in the 
HMEC with serial passage, may reflect a function of either pre-senescent cells still in the 
culture (Schwarze et a l, 2001), or of continuing damage to senescent cells that are 
attempting to repair damage, independent of their growth arrested state. Overall, the 
changes within the HMEC are consistent with an in vitro increase in biological age as a
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function of time. These results suggest that this experiment is a useful model of biological 
ageing and for determining the role of sirtuins in senescence and cancer.
3.3.2 Changes in sirtuin expression
Sirtuins 1,2,3 and 7 (Sirtl,2,3, and 7) were specifically studied as they have been shown 
to participate within the MTR and may provide information on how the MTR senses, 
assesses and signals changes associated with senescence (Ford et al., 2006, Onyango et 
al., 2002, Schwer et al,, 2002). In this study, SIRTl and SIRT2 transcriptional expression 
showed no obvious pattern o f change in successively passaged HMEC, unlike SIRT3 and 
SIRT7 expression, which showed a progressive increase in transcriptional expression with 
increasing passage.
The transcriptional expression of SIRT3 increased in replicatively ageing HMEC. Sirt3 
activity is linked with the availability of fuel, as well as with the oxidative state of the 
cell, via its NAD-dependent enzymatic activity on AceCS2 (Hallows et a l, 2006). In 
HMEC undergoing RS, stresses experienced by the cell may alter NAD levels and result 
in a concomitant fall in Sirt3-mediated enzymatic activity (Schwer et a l, 2002). This 
reduction in Sirt3 activity may result in a fall in the efficiency of fuel utilisation and 
contribute to senescent growth arrest. Increased SIRT3 transcription may result in order to 
increase the efficiency of fuel utilisation and energy production, thereby preventing this 
growth arrest. Sirt3, along with Sirt2, mediates susceptibility to oxidative death via 
activation of the mitochondrial transient receptor potential melastatin-related channel 2
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(TRPM2) (Grubisha et a l, 2006). Increasing levels of Sirt3, with replicative age, may 
reflect the cellular response to mitochondrial damage that accrues with time, leading to 
senescent growth arrest. High levels of Sii*t3 are protective in this context. In vivo 
evidence to support this include the finding that reduction in Sii"t3 expression is 
detrimental for longevity in the elderly (Rose et al., 2003, Bellizzi et al., 2005). Our data, 
that show increasing transcriptional expression of SIRT3 in replicatively ageing 
mammary epithelial cells, are supportive of this.
SIRT7 expression was also seen to increase with RS. As with yeast Sir2, Sirt7 is localised 
to the nucleolus, the site of rDNA where it is also known to associate with condensed 
chromosomes during mitosis (Michishita et a l, 2005). In S. cerevisiae, Sir2 flmctions at 
the rDNA to prevent the recombinational formation of ERCs (Park et a l, 1999). 
Although the accumulation of ERCs does not occur in humans, Sirt7 has been shown to 
activate Pol I-mediated transcription of rRNA, encouraging growth and proliferation 
(Ford et a l, 2005). Paradoxically, senescent fibroblasts exhibit a higher rRNA synthesis 
rate when compared to young cells at similar growth rates, resulting in the generally 
observed higher rRNA content of senescent cells (Halle et a l, 1997). Increasing SIRT7 
expression may reflect this increased rRNA synthesis that occurs as cells become 
senescent. Finally, rRNA transcription may also act as a direct sensor for accumulation of 
DNA damage over a cell’s lifespan (Shiels and Davies, 2003). The repetitive nature of 
the rRNA genes, in combination with the dense loading of the Pol I complexes at the 
active templates, provides a high probability of a polymerase encountering, and stalling 
at, sites of DNA damage. The accumulation of signals associated with such stalled DNA
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polymerases may activate p53 and DNA-damage response path^vays that contribute to 
senescence. Again, our data that show increased SIRT7 expression in replicatively ageing 
mammary epithelial cells are supportive of this.
SIRTl is thought to modulate cellular senescence by negatively regulating p53 (Langley 
et al., 2002, Chua et al., 2005). SIRTl is Icnown to act as a negative regulator of p53 and 
may be important in allowing a cell to resist the gradual accumulation of sub-lethal 
damage that may contribute to the senescent phenotype. SIRTl expression may, therefore, 
be expected to fall as cells undergo RS. This study did not show a fall in SIRTl 
expression in ageing primary HMEC. Although this observation is counterintuitive, the 
evidence for the role of Sirtl in senescence is also conflicting. Although over-expression 
of SIRTl has been shown to rescue mouse epithelial fibroblasts from primary senescence 
(Langley et a l,  2002), other studies have shown that transfection of human fibroblasts or 
human epithelial cells with SIRTl does not affect when senescence occurs (Michishita et 
a l, 2005). în addition, SIRTl transcription and protein expression appears to decrease in 
some fibroblast cell lines but not in others (Michishita et al., 2005, Sklavounou et al., 
2006). Although this supports the observation that over-expression of SIRTl in human 
cancer cells has no effect on their growth (Afshar and Murnane, 1999), the Sirtl inhibitor, 
Sirtinol, has been shown to induce senescence-like growth arrest in MCF-7 cells (Ota et 
a l, 2005). The role of Sirtl on senescence may therefore depend on numerous factors 
including cell type, as well as whether senescence is replicative or stress and aberrant 
signalling-induced (Wright and Shay, 2002). This is analogous to the contrasting role that
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Sirtl has in mediating apoptosis; that is of inducing TNFa-mediated apoptosis but 
protecting against p53~mediated apoptosis (Yeung e ta l ,  2004).
Finally, levels ofSIRT2  also showed no change within the HMEC undergoing RS. This is 
in keeping with the previous observation that SIRT2 expression remains unchanged in 
ageing human fibroblasts (Michishita et a l, 2005). Sirt2 appears to participate in a cell- 
cycle checkpoint during the M phase of mitosis. Although senescence in mammary 
epithelial cells is associated with the accumulation of chromosomal abnormalities their 
presence does not appear to result in an increase in SIRT2 expression at the 
transcriptional level. RS does not, therefore, appear to be associated with Sirt2-mediated 
cell-cycle arrest.
This study has shown that the transcriptional expression o f SIRT3 and SIRT7 is associated 
with replicatively ageing primary mammary epithelial cells. These changes are associated 
with established molecular and biochemical markers of senescence, namely increased 
transcriptional expression p21 and increased SA-p-Gal staining.
88
Chapter 4 
Sirtuin Expression in Non-malignant 
and Malignant Breast Biopsies
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4.1 Introduction
Sirtuins link the functions of the mitochondrion, telomere nucleo-protein complex and 
ribosome production (the MTR), and may be important contributors to a wide range of 
ageing-related diseases including cancer (Shiels and Davies, 2003). Over a cell’s lifespan, 
perturbation in sirtuin activity at each of these loci may result in biological ageing. 
Similarly, changes in sirtuins acting within the MTR may be expected to occur in cancer. 
Indeed, human sirtuins have been implicated in senescence growth arrest (Langley et a l,
2002), apoptosis (Luo et al., 2001, Vergnes et a l, 2002) and cell-cycle regulation 
(Diyden et a l, 2003), processes that are all involved in suppressing the growth of 
abnormal, rapidly proliferating cells, a hallmark of cancer.
Supporting this, are the changes in sirtuin transcriptional expression observed within 
ageing primaiy mammary epithelial cells. Specifically, changes in SIRT3 and SIRT7 
expression, involving the mitochondrial and ribosomal units of the MTR, may be 
predictive of similar changes in sirtuin expression in breast cancer.
4.1.1 Sirtuin expression in cancer
Increased histone deacetylase activity has been shown to provide a growth and survival 
advantage in certain cancers (Marks et a l, 2001). In keeping with this, SIRTl expression 
has been shown to be higher in a number of cancers (Lim, 2006b, Kuzmichev et a l, 2005, 
Chen et a l, 2005, Yeung et a l, 2004, Bradbury et a l, 2005). Sirtuin activators are able to
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cause cellular lifespan extension (Wood et a l, 2004) and SIRTl siRNA can cause cancer 
cells to become senescent (Ota et al., 2005, Ford et al., 2005). Sirtl may contribute to 
tumorogenesis by inhibiting tumour cell apoptosis. It may do this via its interactions with 
proteins that include p53, NF-kB and the Foxo transcription factors (Luo et al.,
2001, Vaziri et al., 2001, Tran et al., 2002, Yeung et al., 2004, Kataoka et al., 2003). 
Normally, Sirtl interacts with these substrates to encourage growth, prevent apoptosis as 
well as to increase a cell’s resistance to stress. Increased expression of Sirtl may provide 
a growth and survival advantage thereby contributing to tumorogenesis. Finally, Sirtl 
might prolong survival of cells at risk for transformation by participating in the silencing 
of tumour suppressor genes (Chen et al., 2005, Pruitt et al., 2006).
The SIRT2 gene is located in a position that frequently undergoes loss of homozygosity in 
human gliomas. Sirt2 is thought to regulate the cell-cycle by preventing its progression in 
cells harbouring chromosomal abnormalities (Dryden et a l, 2003). Proteomic studies 
show a downregulation of Sirt2 to be a feature of gliomas (Hiratsuka et a l, 2003) as well 
as gastric cancers (Inoue et a l, 2006). Marked aneuploidy in gliomas suggest that a 
defective mitotic spindle checkpoint resulting in chromosomal instability occurs 
(Cleveland et a l, 2003). SIRT2 may function as a tumour suppressor gene as its 
downregulation may be responsible for the chromosomal instability that leads to 
tumorogenesis.
The activity of the Sirt3 deacetylase is linked to the oxidative state of the cell. Analogous 
to the role of Sirtl and Sirt2, Sirt3 may also have a role in survival and function to
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prevent cells accumulating mitochondrial damage that may contribute to senescent 
growth arrest (Shiels and Davies, 2003). The in vitro studies have shown that SIRT3 
expression increases in ageing mammary epithelial cells, perhaps in response to the 
stresses associated with replicative ageing. Furthermore, variability of the SIRT3 gene has 
been linked to survival in the elderly (Rose et a l, 2003).
Sirt3 may also have a direct role in tumorogenesis. The gene encoding it has been shown 
to map to a sub-telomeric region that is subject to genomic imprinting. This region also 
contains a major but as yet unidentified tumour suppressor gene as well as a locus 
associated with Beckwith-Wiedemann Syndrome, a syndrome associated with both 
prenatal overgrowth and predisposition to cancer (Shiels, 1999, Shiels and Jardine, 2003, 
Feinberg, 2000, Weksberg et al., 1993, Lee et al., 1999a).
The expression of SIRT7 is invariably elevated in malignant thyroid cancer cell lines and 
biopsies indicating that this represents an important step in thyroid cancer pathogenesis 
(de Nigris et al., 2002, Frye, 2002). In addition, the SIRT7 gene maps to cluomosome 
17q25.3; a region that is frequently affected by chromosomal alterations in acute 
leukaemias and lymphomas (Voelter-Mahlknecht et a l, 2006). Increased nucleolar yeast 
Sir2 activity results in a decrease in ERCs and prolongation of lifespan. Similarly, Sirt7 
also displays nucleolar localisation and has been shown to activate Pol I and rDNA 
transcription, thereby promoting cell growth and proliferation (Ford et a l, 2006). The in 
vitro studies suggest that, like yeast Sir2, Sirt7 levels may determine the stage at which
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cells become senescent. An increased expression of SIRT7 may provide tumour cells with 
a survival advantage contributing to tumorogenesis.
In summary, as with senescence, tumorogenesis may be associated with changes within 
the components of the MTR. Specifically, in cancer cells, altered sirtuin expression may 
be associated with a perturbation in damage responses that normally contribute to 
biological ageing and senescence. The study of sirtuin expression, relating to components 
of the MTR, in cancer may help in understanding how cancer develops and progresses 
from a platform of biological ageing. In the previous chapter, sirtuin transcriptional 
expression was demonstrated to change as a functional of biological ageing. This analysis 
can be extended to in vivo situation by looking at how sirtuin expression in breast tissue 
biopsies is tied to disease status.
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4.1.2 Aims
The purpose of this part of the study was to determine if changes in biological ageing 
observed in the HMEC are pertinent to the situation in vivo. This was achieved by 
studying sirtuin expression in non-malignant and malignant breast tissue biopsies.
Individual questions addressed were;
1. Does sirtuin transcriptional expression differ between non-malignant and 
malignant breast tissue biopsies?
2. Is the transcriptional expression of sirtuins indicative of breast cancer 
histopathology or tumour stage?
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4.2 Results
Sirtuin expression was investigated in breast cancer to determine if changes in the 
transcriptional expression of individual sirtuins correlated with malignancy and disease 
stage. Sirtuin expression was measured, in archival non-malignant and malignant breast 
biopsies collected and stored within the Department of Surgeiy at the University of 
Glasgow, using Taqman real-time relative quantitative PCR.
4.2.1 Summary of breast biopsies analysed
The pathological characteristics o f the breast biopsies were selected to include equal 
distribution by nodal status (12 lymph node positive and 12 lymph node negative) as 
nodal status has been shown to be one of the most important indicators o f breast cancer 
prognosis (Russo and Russo, 2003). A total of 24 breast cancer samples were chosen and 
matched with 21 non-malignant breast tissue biopsies fr om the breasts of cancer patients. 
Both groups were well matched with the mean age of the patients in the cancer biopsy 
group being 62.3 years (SEM 3.1) and that of the non-malignant biopsy group, 61.4 
(SEM 3.1). All tumours were ductal adenocarcinomas and both groups had a similar 
histopathology, oestrogen receptor status and size (Table 4.1).
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4.2.2 Sirtuin expression in breast biopsies
Relative SIRT7 gene expression was significantly greater in biopsies from breast cancers 
compared to non-malignant breast tissue 1.45 (95% C.I. 1.19 -  1.71) vs. 0.83 (95% C.I. 
0.68 -  0.99), p<0.001 (Figure 4.1). The relative expression of SIRT7 was also 
significantly higher in node positive compared to non-malignant breast biopsies 1.63 
(95% C.I. 1.27 -  1.99) vs. 0.83 (95% C.I. 0.68 -  0.99), p<0.001 (Figure 4.2).
No significant differences in SIRTl, SIRT2 and SIRT3 gene expression were observed in 
a simple comparison of breast cancer biopsies with non-malignant breast tissue biopsies 
(Figure 4.1). However, analogous to SIRT7 expression, SIRT3 expression was also 
significantly higher in lymph node positive breast cancer biopsies when compared to non- 
malignant breast biopsies, 0.62 (95% C.I. 0.46 -  0.78) vs. 0.40 (95% C.I. 0.30 -  0.49), 
p<0.05 (Figure 4.2).
Sirtuin expression was similarly compared by grade, oestrogen receptor status and the 
presence of lymphovascular invasion in both node positive and node negative cancers. No 
significant association between sirtuin expression and these factors was observed.
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Figure 4.1 Sirtuin expression in non-malignant and breast cancer biopsies. 
Histograms show relative sirtuin gene expression in non-malignant and malignant breast 
biopsies, relative to an 18S rRNA conti'ol. Data show mean sirtuin expression ± s.e.m.
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Figure 4.2 SIRT3 and SIRT7 expression in breast biopsies by nodal status. The
histogram shows relative SIRT3 and 7 gene expression in non-malignant and lymph node 
positive and negative breast cancer biopsies. Data are plotted as mean sirtuin expression 
± s.e.m.
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4.3 Discussion
4.3.1 Sirtuin expression in breast cancer
A number of Unes of evidence suggest sirtuins are implicated in cancer (de Nigris et ai., 
2002, Frye, 2002, Pruitt et al., 2006, Ota et al., 2006, Neumeister et al., 2002, Hiratsuka 
et al., 2003, Chen et al., 2005). Our data are consistent with these, showing increased 
SIRT7 expression to be a feature of breast cancer. This increased expression may reflect a 
molecular change necessary for breast cancer tumorogenesis. Furthermore, SIRT7 
expression was also associated with nodal invasion and, therefore, with more invasive 
tumours and more aggressive disease. Proliferating cells have a higher demand for 
ribosomes than slowly proliferating cells. Since the rapid growth of tumours requires 
elevated rates of ribosome biosynthesis, Pol I transcription may need to increase during 
tumorogenesis. Indeed, levels of rDNA transcription are increased in transformed cells 
and the corresponding increase in nucleolar size is often used as a prognostic marker for 
the rapidity of cancer-cell proliferation (Russo and Russo, 2003).
The question remains as to whether the deregulation of rRNA synthesis contributes to the 
increased proliferative potential of mammary cancer cells, plays a secondary, but 
necessary, part in supporting the increased cell growth or, alternatively, is a 
compensatory mechanism as a consequence of the increased proliferative state. The latter 
hypothesis is supported by obsei*vations on the activity of the yeast sirtuin orthologue, 
SIR2. Nucleolar Sir2 activity is a limiting factor for determining when the cell undergoes 
senescence (Guarente, 1999). The high proliferative rate in many tumours, often results in
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them having shortened telomeres as a consequence of rapid cell turnover outstripping 
telomerase-mediated telomere repair. This may, analogous to the situation in yeast 
(Guarente, 1999), lead to an up-regulation of sirtuin activity in an attempt to stabilise the 
nucleolus. The increased SIRT3 and SIRT7 transcription observed in primary mammary 
epithelial cells, as a consequence of increased oxidant load with in vitro growth, is also 
supportive of such a scenario.
At first glance, no difference in SIRT3 transcriptional expression was observed in breast 
cancer biopsies. However, on subdividing tumours by nodal status, levels of SIRT3 are 
observed to be higher in the prognostically poorer lymph node positive tumours compared 
to normal breast biopsies. Similarly, increased SIRT3 expression was observed in ageing 
primary mammary epithelial cells. Sirt3 has been shown to be specifically targeted and 
converted into its active form within the mitochondria (North et al., 2003, Dryden et al.,
2003). Cumulative mitochondrial damage contributes to a fall in relative NAD levels, a 
concomitant fall in Sirt3 activity, and is associated with growth arrest, senescence and 
apoptosis (Shiels and Davies, 2003). Correspondingly, increased growth and proliferation 
is associated with an increase in mitochondrial activity and Sirt3-mediated energy 
production (Hallows et a l, 2006). Increased SIRT3 expression, observed in the node 
positive breast cancer biopsies, may reflect this. Analogous to Sirtl and Sirt2, increased 
SIRT3 expression may provide ageing mammary epithelial cells with a growth and 
survival advantage and may also contribute to tumorogenesis in breast cancer. Although 
differences in SIRT3 expression were only observed on subdividing tumours by nodal 
status, it may be that, by increasing the study size, we find a difference in SIRT3 
expression between non-malignant and breast cancer biopsies.
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Surprisingly, transcriptional changes in SIRTl expression did not appear to be implicated 
in breast cancer pathogenesis in this study. This is substantiated by the results of studies 
on ageing primary mammary epithelial cells which showed no association between SIRTl 
transcriptional expression and replicative senescence. Collectively, these findings 
suggest that aberrant Sirtl transcriptional activity is not implicated in breast cancer 
pathogenesis. This data appear to be at odds with those from groups that have shown 
increased levels of SIRTl expression in a number of cancers (Luo et ah, 2001, Lim, 
2006b, Yeung et al., 2004, Kuzmichev et al., 2005, Chen et al., 2005). Indeed, Sirtl 
interacts with a number of proteins involved in cancer pathogenesis including 
p53, H lCl, the Foxo transcription factors and NF-kB (Kataoka et al,, 2003, Chen et al., 
2005, Yeung et al., 2004, Langley et al., 2002, Yang et al., 2005). Therefore, although 
these data suggest that Sirtl is not implicated in breast cancer pathogenesis, it cannot be 
excluded, as these experiments looked at a small number of tumour biopsies, did not look 
at whether SIRTl expressed was mutated and, crucially, did not look at any putative post- 
transcriptional regulation.
Finally, no difference in SIRT2 transcriptional expression was observed in breast cancer 
biopsies compared with non-malignant breast biopsies. Again, this substantiates the 
findings from the in vitro studies and, like Sirtl, suggests that changes in Sirt2 are not 
implicated in breast cancer pathogenesis. Sirt2 has been shown to interact with and 
deacetylate the a-tubulin subunit of microtubules and is thought to participate in a late 
mitotic check-point to ensure correct chromosome segregation during cytokinesis (North 
et ah, 2003, Dryden et ah, 2003). Sirt2 may perform a regulatory function that prevents
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cells with chromosomal abnormalities from dividing. Chromosomal fusions are 
commonly seen in cancer cells and decreased SIRT2 expression is a feature of gliomas 
and gastric cancer (Hiratsuka et al., 2003, Inoue et al., 2006). Chromosomal instability 
appears early during breast carcinogenesis and is considered a major driving force in 
malignant transformation (Meeker and Argani, 2004). Unlike defects in BRCA gene 
expression, a common feature of breast cancer and known cause of chromosomal 
instability and aneuploidy (Daniels et ah, 2004, Grigorova et al., 2004), decreased SIRT2 
transcriptional expression does not appear to account for the increased chromosome 
instability observed in breast cancer. Despite these results, SIRT2 expression and activity 
is cell-cycle dependent (Dryden et al., 2003, North et al., 2003) and it may be that more 
dynamic evaluation of changes in SIRT2 expression at specific stages of the cell-cycle 
may reveal abnormal patterns of SIRT2 expression in breast cancer. Again, it must be 
noted that these experiment looked at a small number of tumour biopsies and did not look 
at any putative post-transcriptional regulation.
This study has validated the in vitro work, and shown increased transcriptional expression 
of SIRT7 to be associated with breast cancer. Furthermore, it has shown that the 
transcriptional expression of both SIRT3 and SIRT7 is associated with lymph node 
positive disease. These sirtuins act at the mitochondrial and ribosomal components of the 
MTR and support the hypothesis that perturbation in these components is associated with 
tumorogenesis.
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Chapter 5
Sirtuin Expression as an Evaluator of Breast
Cancer Therapy
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5.1 Introduction
Breast cancer treatment invariably involves surgery, as well as adjuvant therapy that 
include radiotherapy and chemotherapy. These treatments result in tumour cell death by 
inducing apoptosis and replicative cell death. Sirtuins have been implicated in apoptosis 
and in cell survival in response to a variety of stresses (Mostoslavsky et ah, 2006, Tran et 
ah, 2002, Chen et ah, 2005, Matsushita et ah, 2005, Luo et ah, 2001). Sirtuin activity 
may, therefore, mediate damage responses in response to irradiation and chemotherapy. 
In the following sections, follows a review of how irradiation and taxane chemotherapy 
cause cell damage, and of how sirtuins may mediate damage responses.
5.2 Cellular irradiation
Cellular irradiation is commonly used for the treatment of breast cancer and involves the 
delivery of ionising radiation with high-energy photons such as y-rays and x-rays. The 
ionisation of tissue water results in the formation of reactive oxygen species (ROS) that 
cause oxidative damage to the cell (Ward, 1988). Radiation produces cell death by either 
apoptosis or replicative cell death. Apoptosis occurs as a consequence of genotoxic insult, 
leading to mitochondrial dysfunction and destabilisation of telomere nucleo-protein 
complexes (Figure 1.5) (Shiels and Davies, 2003). Replicative cell death occurs when 
cells with unrepaired DNA strand breaks pass through mitosis resulting in the formation 
of lethal chromosomal aberrations (Revell, 1983). It is replicative cell death that 
predominates after exposure to ionising radiation (Steel, 2001).
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5.2.1 Ionising radiation and DNA repair
Common types of damage induced by ionising radiation include oxidative DNA base 
damage, as well as single-strand breaks (SSB) and double-strand breaks (DSB) within the 
DNA duplex. Non-repaired radiation induced DSB are frequently lethal and radiation 
killing is inversely proportional to their rate of repair (Pawlik and Keyomarsi, 2004). Two 
major pathways of DSB repair have been identified: homologous and non-homologous 
recombination (Figure 5.1) (Valerie and Povirk, 2003, Meselson and Radding, 1975).
In homologous recombination (HR), the DSB is processed to a single-stranded region by 
a nuclease and helicase. A nucleoprotein filament forms on the single-stranded DNA and 
identifies homologous DNA to be used as a template to direct accurate repair. The 
missing sequences are restored by the activities of a DNA polymerase and ligase. Finally, 
resolution of the crossed DNA strands, known as "holiday junctions", yields two intact 
duplexes (Figure 5.1) (Valerie and Povirk, 2003). Non-homologous recombination or 
end-joining (NHEJ) predominates in mammalian cells and involves many proteins 
including the binding to DNA of the Ku heterodimer and the recruitment of DNA-PKC 
(Hartley et a i, 1995). The DNA ends are brought together, processed and ultimately 
joined by a ligase (Figure 5.1).
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Figure 5.1 Homologous and non-homologous DNA repair. This figure shows the 
major steps in both homologous and non-homologous recombination of DSB repair. 
[Figure adapted from Valerie and Povirk, (2003)].
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The link between the cell-cycle and DNA damage occurs through cell-cycle sensing of 
DNA breaks and transduction of signals through key proteins such as ATM and p53 
(Samuel et a l, 2002). The exact sequence of interactions of these proteins remains to be 
elucidated.
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5.2.2 Cell-cycle and ionising radiation
Cells commonly respond to ionising radiation-induced DNA damage by activating cell- 
cycle checkpoints. Major cell-cycle checkpoints occur at the Gi and G2, controlling entry 
of cells into the S and M phases respectively. Checkpoints also exist during the S and M 
phases (Figure 5.2).
Figure 5.2 Cell-cycle checkpoints. This figure shows the Go, M and S phases of the cell- 
cycle as well as the Gi, S, G2 and M cell-cycle checkpoints.
Q8 Arreat
The Gi checkpoint arrest is promoted by p53, with post-translational modifications 
increasing the protein’s half-life and resulting in a transient increase in levels of activated 
p53 protein (Kastan et a l, 1992). DNA strand breaks are the most potent inducer of p53 
following ionising radiation. Cell-cycle arrest is induced by the trans-activation of the 
p2 icrpi that interacts with the cyclinE/CDK2 complex, inhibiting the progression
of cells into the S phase (Figure 5.3) (Samuel et a l,  2002).
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Figure 5.3 The cell-cycle and radiation damage. This figure shows where sirtuins may 
interact with components of the damage response machinery, thereby contributing to cell- 
cycle arrest, following ionising radiation. [Figure adapted from Samuel et a l, (2002)].
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Following the Gi checkpoint, there is the S phase checkpoint. This regulates the initiation 
and elongation stages of DNA replication and is also inhibited by ionising radiation 
(Maity et a i, 1994). Radiation signalling pathways may interact with DNA replication 
processes in mammals via ATM, a protein that also plays a role in replicon initiation and 
chain elongation (Valerie and Povirk, 2003). It has been well established that mutations 
in the ATM  gene result in oversensitivity to radiation-induced DNA damage (Taylor et 
a l, 1975).
A prolonged cell-cycle arrest in Gz occurs in almost all eukaryotic cells following
exposure to ionising radiation (Maity et a l,  1994). This G2 arrest may perform a
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surveillance function in cells to prevent those with DNA damage from undergoing 
mitosis. ATM activates the CHK2 protein that subsequently inhibits CDKl and causes G2 
phase arrest (Figure 5.3) (Samuel et a l, 2002). The p53 protein also triggers arrest at this 
checkpoint by the transcription of 14-3-3a that can also inhibit CDKl. The M phase 
checkpoint phase follows the G2 phase and ensures correct chromosome alignment. It is 
at this checkpoint that damage to microtubules that would lead to aberrant mitosis is 
detected. This is pertinent to drug-induced cellular damage from agents that include vinca 
alkaloids and taxanes.
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5.3 Taxanes
Taxanes are employed as adjuvant therapy for the management of breast cancer. The role 
of this chemotherapeutic is explored below with respect to cell damage responses. 
Taxanes belong to a class of chemotherapeutic, derived from the bark and leaves of the 
Pacific yew tree. Their mechanism of action, is via the inhibition of microtubule function, 
although how this exactly occurs is poorly understood (Hudis, 1999)
5.3.1 Cell-cycle and taxanes
To understand how taxanes function, we must refer to the cell-cycle (Figure 5.1). As 
previously mentioned, DNA damage prevents Gi cells from entering the S phase and Gz 
cells from entering the M phase of mitosis.
The M phase checkpoint monitors the alignment of chromosomes on the mitotic spindle, 
ensuring a complete set of chromosomes is distributed accurately to the daughter cells. 
The failure of one or more chromosomes to align properly on the spindle causes mitosis 
to arrest at the metaphase, prior to the segregation of the newly replicated chromosomes 
to daughter nuclei. As a result of this checkpoint, the chromosomes do not separate until a 
complete complement of chromosomes has been organised for distribution to each 
daughter cell (Cleveland et a l, 2003).
The mechanism of action of the taxane chemotherapeutic, paclitaxel, is thought to be via 
the disruption of normal microtubule dynamics (Hudis, 1999). This results in mitotic cell-
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cycle arrest at the M phase checkpoint and cell death. Paclitaxel exposure is also 
associated with increased microtubule acétylation and therefore stability (Piperno et al., 
1987, Marcus et al., 2005). Deacetylases, such as the sirtuins, can affect microtubule 
structure and stability, and may determine the efficacy of paclitaxel therapy. Indeed 
sirtuins may also influence the efficacy of other cancer therapies (Marks et a l, 2001).
5.4 Sirtuins and cancer therapy
In the preceding experiments, sirtuin expression was linked with biological ageing in 
primary epithelial cells, and was also shown to be associated with lymph node positive 
breast cancer. These results support a role for sirtuins in mammary epithelial cell 
survival. Similarly, sirtuins may also mediate the response of breast cancer cells to both 
radiotherapy and paclitaxel chemotherapy (Mostoslavsky et al., 2006, Tran et al., 2002, 
Chen et al., 2005, Matsushita et al., 2005). In the following sections, the mechanisms by 
which sirtuins may function in damage responses to both of these treatments are 
explored.
5,4.1 Radiotherapy
In response to radiation-induced DNA damage, Sirtl allows the repair of DNA damage 
by inhibiting the p53 protein (Vaziri et al., 2001, Luo et al., 2001). Substantiating the role 
of Sirtl in protecting against radiation-induced apoptosis, cells transfected with SIRTl 
display an increase in radioresistance, while conversely, deletion of SIRTl results in 
radiosensitivity (Luo et al., 2001, Cheng et al., 2003). In vivo studies confirming this have
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been equivocal, with reports detailing thymocytes from SIRTl null mice displaying p53 
hyperacetylation after DNA damage and increased radiation-induced apoptosis, and 
others showing no difference (McBurney et al., 2003, Cheng et al., 2003, Kamel et al., 
2006). Although various explanations for these differences have been proposed, the exact 
reason remains to be determined (Kamel et a l, 2006).
Cell irradiation causes chromosomal instability that results in replicative cell death 
(Revell, 1983). Sirt2 participates in a cell-cycle checkpoint role whereby it detects the 
presence of chromosomal abnormalities and may arrest the division of irradiated cells 
that harbour them (Figure 1.6) (Dryden et al., 2003, Inoue et al., 2006). Indeed, increased 
levels of the Sirt2 protein are seen at the G^/M phase transition and are persistently high 
during the M phase of the cell-cycle (Diyden et al., 2003, Vaquero et al., 2006, Inoue et 
al., 2006).
Irradiation can induce oxidative damage within the cell by the formation of ROS (Maity 
et a l, 1994). The resultant fall in the NAD/NADH ratio may result in decreased Sirt3 and 
concomitantly, AceS2 activity (Hallows et a l, 2006). This would result in a fall in the 
efficiency of fuel utilisation and energy production and in an increase in the generation of 
toxic metabolites that contribute to cell death. The mitochondrion itself is also a key 
regulatory centre of apoptosis (Pollack et a l, 2002) and can induce apoptosis in a 
caspase-dependent or independent manner (Danial and Korsmeyer, 2004). Sirt3 may be 
implicated in resistance to ionising radiation-induced damage, not only by improving fuel 
utilisation and energy production but also by directly sensing and responding to the redox 
state of the cell (Smith et al., 2000, Onyango et al., 2002, Schwer et al., 2002).
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Sirt6 and Sirt7 closely associate with chromosomes during mitosis and, like Sirt2, may 
participate in a cell-cycle checkpoint. Sirt6 has been shown to promote resistance to DNA 
damage and suppress genomic instability by participating in DNA repair (Mostoslavsky 
et al., 2006). Sirt7 has been shown to play a role in Pol 1-mediated transcription, and its 
depletion prevents cell proliferation and triggers apoptosis (Ford et al., 2006).
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5.4.2 Chemotherapy
Chemotherapeutic s act in a number of different ways. Anthracyclines mediate much of 
their toxicity through the production of free radicals, etoposide by inhibiting 
topoisomerase II activity and taxanes by the disruption of microtubules. Sirtuins have 
been implicated in preventing cell death resulting from anthracyclines (Chu et a l, 2005) 
and topoisomerase II inhibitors (Cheng et a l, 2003) but have not been studied with 
respect to taxanes,
Taxane therapy is thought to induce cell damage by microtubule disruption (Hoiwitz, 
1992) and is associated with increased microtubule acétylation (Marcus et a l, 2005). 
Sirt2 deacetylates microtubules at the M phase of the cell-cycle resulting in mitotic arrest. 
It is hypothesised, that in this way Sirt2 prevents cell division in cells harbouring 
chromosomal abnormalities (Dryden et a l, 2003). Taxanes cause chromosomal 
abnormalities resulting in M phase arrest and may trigger the expression of SIRT2. 
Recently, Sirt2 has been shown to prevent microtubule poison-induced hyperploid cell 
formation, via a block of entiy to chromosome condensation (Inoue et a l, 2006). 
Interestingly, both Sirt6 and Sirt7 also closely associate with condensed chromosomes 
during mitosis and may, like Sirt2, be involved in cell-cycle control (Michishita et a l, 
2005).
A role for Sirtl has also been postulated for drug resistance in breast cancer treated with 
paclitaxel (Chu et a l, 2005). Pertinent to this, is the observation that SIRTl regulates the 
mdrl gene, implicated in paclitaxel resistance in breast cancer (Mechetner et a l, 1998).
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Treatment with paclitaxel may, therefore, be expected to promote SIRTl transcription. In 
the MCF-7 breast cancer cell line, levels of the FoxoSa protein increase dramatically after 
paclitaxel treatment (Sunters et a i, 2003). Sirtl increases the ability of Foxo3a to induce 
cell-cycle arrest and promote resistance to oxidative stress but inhibits its ability to induce 
cell death. Increased Sirtl transcription may, therefore, tip Foxo-dependent responses 
away from apoptosis toward stress resistance facilitating repair (Brunet et al., 2004, 
Motta et al., 2004, Nemoto et al., 2005).
Paclitaxel has also been reported to affect mitochondrial apoptotic mechanisms by 
interfering with the mMPTP (Evtodienko et a i, 1996). In addition, paclitaxel, may induce 
apoptosis by directly inducing ROS formation within the mitochondria (Varbiro et a l, 
2001), These may result in a changes in NAD/NADH dynamics thereby impacting on 
Sirt3 activity. Specifically, a fall in the cellular NAD/NADH ratio, as a result of ROS 
formation, would result in inhibition of mitochondrial sirtuin activity. Mitochondrial Sirt3 
levels may predict resistance to paclitaxel-induced cell death.
Sirtuin activity, within different components of the MTR, link DNA damage responses. 
Consequently, an imbalance in sirtuin activity within any individual part of the MTR may 
result in the dysregulation of normal growth, proliferation and apoptosis (Shiels and 
Davies, 2003). Abnormalities in sirtuin expression within tumour cells, may affect the 
way in which these cells response to damage compared to non-malignant tissue (Chu et 
al., 2005, Ota et al., 2006).
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In the preceding studies, sirtuins have been shown to be associated with replicative 
senescence and cancer. This part of the study, sought to determine the relationship 
between sirtuin transcriptional expression in tumour cells in response to damage from 
standard cancer therapies, namely radiotherapy and chemotherapy. Specifically, sirtuin 
expression was investigated in breast cancer cell lines in response to ionising radiation 
and paclitaxel therapy. Studies were performed on breast cancer cell lines expressing 
wild-type and mutant, inactive, p53. These breast cancer cell line were selected, as 
sirtuins are implicated in the regulation of p53 (Vaziri et al., 2001, Langley et al., 2002) 
and may themselves be regulated by this protein (Nemoto et a l, 2004).
Transcriptional expression of was studied as it is a good indicator of radiation
damage responses (Figure 5.3) (Samuel et a l, 2002). Transcriptional expression of 
SIRT1,2,3 and 7 was studied as these sirtuins act within components of the MTR that are 
implicated in apoptosis and cell-cycle arrest (Figure 1.5 and 1.6) (Dryden et al., 2003, 
Hiratsuka et al., 2003, Inoue et al., 2006, Vaziri et al., 2001, Luo et al., 2001).
Finally, TUNEL assays were performed to determine whether breast cancer cells studied 
displayed resistance to radiation-induced apoptosis and, if so, whether this occurred in a 
sirtuin-mediated manner.
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5.5 Aims
In this part of the study, sirtuin expression was used to evaluate breast cancer therapies 
including ionising radiation and paclitaxel, chemotherapy.
Individual questions addressed were:
1. Does sirtuin transcriptional expression alter following ionising radiation in breast 
cancer cells?
2. Does sirtuin transcriptional expression alter following paclitaxel chemotherapy in 
breast cancer cells?
3. Is the transcriptional expression of any individual sirtuin reportive for ionising 
radiation or paclitaxel chemotherapy?
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5.6 Results
Transcriptional expression of sirtuins was evaluated in breast cancer cells following 
ionising radiation and paclitaxel treatment. The results are described below in separate 
sections delineating each of these treatments.
5.6.1 Cellular Irradiation
Two breast cancer cell lines were chosen for this study, namely the MCF-7 cell line, 
expressing wild-type p53, and the MDA-MB-231 cell line, expressing mutant p53. Breast 
cancer cells were subjected to 2 to 10 Grays of radiation, corresponding to the maximal 
radiation dose range for the treatment of breast cancer (Arnold et a l, 1999). The cultures 
were assessed for the effects of acute sti ess via real-time Taqman PCR analysis of p2î^^^^ 
transcription, as well as transcription of SIRT1,2,3 and 7 at 24 and 48 hours after 
irradiation. Sirtuin transcriptional expression was studied at the 24 and 48 hour time- 
points as ionising radiation influences cell-cycle progression and cell-cycle checkpoints 
that result in replicative cell death (Pawlik and Keyomarsi, 2004).
A dose related increase in p21^^^^ expression was observed in the MCF-7 cells at 24 
hours (R^ = 0.856, p<0.001) and at 48 hours (R^ = 0.925, p<0.001) after irradiation (Table 
5.1, Figure 5.4). A dose related increase in SIRT2 (R^= 0.687, p=0.001) and SIRT7 (R^ = 
0.875, p<0.001) expression was also observed in the MCF-7 cells 48 hours after 
irradiation (Table 5.1, Figures 5.6 and 5.8). A dose related increase in was only
observed in the MDA-MB-231 cell line at 48 hours after irradiation R  ^^  0.492, p=0.011).
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Similar to the MCF-7 cells, an increase in SIRT2 (R^ = 0.560, p=0.005) and SJRT7 (R^ = 
0.710, p=0.001) expression was also observed at 48 hours after irradiation (Figures 5.6 
and 5.8). Neither of the cell lines showed any relationship between cellular irradiation 
and SIRTl or SIRT3 transcription at either of the timepoints (Figures 5.5 and 5.7).
A TUNEL assay was used to evaluate the degree of apoptosis in the irradiated cell lines. 
Both breast cancer cell lines showed substantial resistance to radiation-induced apoptosis 
at the radiation doses employed (Figure 5.9 and 5.10).
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Table 5.1 Relationship between irradiation dose and sirtuin and p21 expression. The
table shows linear regression analyses for the relationship between irradiation dose and 
sirtuin and transcriptional expression at 24 and 48 hours after treatment in MCF-7
and MDA-MB-231 mammary cancer cell lines. values and p-values are displayed. 
*p<0.05, **p<0.01,, ***p<0.001
MDA-MB-231
24 hrs 48 hrs
MCF-7 R^ p-value R^ p-value
P21 0.856 0.000** 0.925 0.000**
SIRTl 0.157 0.202 0.055 0.465
SIRT2 0.277 0.079 0.687 0.001**
SIRT3 0.156 0.203 0.147 0.219
SIRT7 0.241 0.105 0.875 0.000**
P21 0.086 0.355 0.492 0,011*
SlRTi 0.002 0.888 0.062 0.436
S1RT2 0.287 0.073 0.560 0.005**
S1RT3 0.008 0.789 0.212 0.132
S1RT7 0.065 0.425 0.710 0.001***
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Figure 5.4 p21 expression in irradiated m am m ary cancer cell lines. The scatterplots 
show irradiation dose plotted against transcriptional expression at 24 and 48
hours after treatment in MCF-7 and MDA-MB-231 mammary cancer cell lines. Lines of 
‘best fit’ are displayed where tests of linear regression showed a statistically significant 
relationship. (n=2)
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Figure 5.5 SIRTl expression in irradiated mammary cancer cell lines. The
scatterplots show irradiation dose plotted against SIRTl transcriptional expression at 24 
and 48 hours after treatment in MCF-7 and MDA-MB-231 mammary cancer cell lines. 
Lines of ‘best fit’ are displayed where tests of linear regression show a statistically 
significant relationship. (n=2)
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Figure 5.6 SIRT2 expression in irradiated mammary cancer ceil lines. The
scatterplots show irradiation dose plotted against SIRT2 transcriptional expression at 24 
and 48 hours after treatment in MCF-7 and MDA-MB-231 mammary cancer cell lines. 
Lines of ‘best fif are displayed where tests of linear regression show a statistically 
significant relationship. (n=2)
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Figure 5.7 SIRT3 expression in irradiated mammary cancer cell lines. The
scatterplots show irradiation dose plotted against SIRT3 transcriptional expression at 24 
and 48 hours after treatment in MCF-7 and MDA-MB-231 mammary cancer cell lines. 
Lines of ‘best fit’ are displayed where tests of linear regression show a statistically 
significant relationship. (n=2)
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Figure 5.8 SIRT7 expression in irradiated mammary cancer cell lines. The
scatterplots show irradiation dose plotted against SIRT7 transcriptional expression at 24 
and 48 hours after treatment in MCF-7 and MDA-MB-231 mammary cancer cell lines. 
Lines of ‘best fit’ are displayed where tests of linear regression show a statistically 
significant relationship, (n-2)
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Figure 5.9 TUNEL assay controls.
a) Negative control (i). Apoalert assay image of MDA-MB-231 breast cancer cells at 
48 hours after irradiation with 10 Grays in the absence of Tdt enzyme. Red colour 
represents nuclear Propidium Iodide staining and green colour, staining of 
terminal DNA strand breaks.
b) Negative control (ii). Apoalert assay image of MDA-MB-231 breast cancer cells 
at 48 hours not subjected to irradiation. Red colour represents nuclear Propidium 
Iodide staining and green colour, staining of terminal DNA strand breaks.
c) Positive control. Apoalert assay image of MDA-MB-231 breast cancer cells 
treated with DNase I. Red colour represents nuclear Propidium Iodide staining 
and green colour, staining of terminal DNA strand breaks.
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(a) Negative control (i)
(b) Negative control (ii)
(c) Positive control
Figure 5.10 TUNEL assays in MCF-7 and MDA-MB-231 cell lines after irradiation.
Apoalert assay images of (a) MCF-7 and (b) MDA-MB-231 breast cancer cells at 24 and 
48 hours after irradiation with 10 Grays. Red colour represents nuclear Propidium Iodide 
staining and green colour, staining of terminal DNA strand breaks.
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5.6.2 Paclitaxel treatment
Cells from the MCF-7 breast cancer cell line were exposed to increasing concentrations 
of the taxane, paclitaxel. The concentrations of paclitaxel used were based on previous 
studies (Blagosklonny et a l, 2002). The cultures were then assessed for the effects of 
acute stress via real-time Taqman PCR analysis of and SIRT1,2,3 and 7
transcription. As previously stated, is a good indicator of damage response and
SIRT1,2,3 and 7 are implicated in apoptosis, cell-cycle control, senescence and tumour 
proliferation respectively (Vaziri et al., 2001, Langley et al., 2002, Dryden et al., 2003, 
Inoue et al., 2006, Hiratsuka et al., 2003, de Nigris et al., 2002).
A statistically significant dose related increase in p21^^^^ (R^ = 0.817, p=0.002), SIRT2 
(R^= 0.861, p=0.001) and SIRT7 (R^= 0.821, p=0.002) expression was seen in the MCF- 
7 cells after paclitaxel treatment (Table 5.2 and Figures 5.11 and 5.12). No association 
was seen between paclitaxel treatment and SIRTl or SIRT3 expression (Figure 5.12). 
These results mirrored those from the irradiation experiments.
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Table 5.2 Relationship between paclitaxel exposure and sirtuin and p21 expression.
The table shows linear regression analyses for the relationship between paclitaxel dose 
and siituin and transcriptional expression in MCF-7 mammary cancer cell lines,
values and p-values are displayed. * p<0.01
MCF-7 R^ p-value
P21 0.817 0.002*
SIRTl 0.038 0.645
SIRT2 0.861 0.001*
SIRT3 0.034 0.660
SIRT7 0.821 0.002*
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Figure 5.11 p21 expression in MCF-7 cells treated with paclitaxel. The scatterplots 
show paclitaxel dose plotted against transcriptional expression in the MCF-7 cell
line. Lines of ‘best fit’ are displayed where tests of linear regression show a statistically 
significant relationship, (n=2)
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Figure 5.12 Sirtuin expression in MCF-7 cells treated with paclitaxel. The scatterplots 
show paclitaxel dose plotted against sirtuin transcriptional expression in the MCF-7 cell 
line. Lines of ‘best fit’ are displayed where tests of linear regression show a statistically 
significant relationship. (n=2)
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5.7 Discussion
5.7.1 Radiotherapy
Ionising radiation results in cellular damage including damage to DNA. At the centre of 
the radiation response, is the p53 protein, which induces cell-cycle arrest and apoptosis 
(Pawlik and Keyomarsi, 2004). The activity of p53 is inhibited by the Sirtl deacetylase 
which may function, like its yeast Sir2 orthologue, in facilitating DNA damage repair 
(Tsukamoto et al., 1997, Lee et al., 1999b). In addition, p53 has itself been shown to 
control SIRTl expression (Nemoto et a l,  2004). It has, therefore, been hypothesised that 
p53 activity may also impact on the expression of the other sirtuins. In order, to 
determine the role of p53 in sirtuin expression in mammary cancer cells in response to 
ionising radiation, the expression of sirtuins was studied in MCF-7 cells expressing 
active, wild-type p5S, as well as in MDA-MB-231 cells, expressing inactive, mutant p53 
(O'Connor et a l, 1997), Although sirtuin responses to ionising radiation occur early they 
may also be influenced by cell-cycle progression and cell-cycle checkpoints, that result in 
replicative cell death (Dryden et al., 2003, Inoue et al., 2006, Michishita et al., 2005, 
Mostoslavsky et al., 2006). Sirtuin expression was therefore studied at both 24 and 48 
hour time points post irradiation in order to allow for the accumulation of cell-cycle 
arrested, damaged cells.
The dose-dependent increase in expression in the MCF-7 cells, but not in the
MDA-MB-231 cells at 24 hours after irradiation reflects the difference in functioning p53
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(Bartek et al., 1990, Watson et al., 1997). There was a smaller increase in 
expression in the MDA-MB-231 cells at 48 hours after irradiation, independent of p53, in 
keeping with previous obseiwations (Macleod et a i, 1995). Despite these changes, both 
cell lines were resistant to radiation-induced apoptosis (Figure 5.8). This observation 
confirms those from previous studies, that have shown both cell lines to be relatively 
resistant to radiation-induced apoptosis independent of p53 activity (Watson et a l, 1997).
The dose-dependent increase in SIRT2 expression observed in both breast cancer cell 
lines, is consistent with the role of Sirt2 in arresting the cell-cycle in response to 
chromosomal damage. Cellular irradiation is known to result in chromosomal instability 
and an increase in chromosomal abnormalities (Revel1, 1983). During the M-phase of 
mitosis, these abnormalities would result in mitotic arrest (Dryden et a l, 2003). Sirt2 has 
recently been shown to prevent drug-induced hyperploid cell formation via a block of 
entry to chromosome condensation (Inoue et a l, 2006). The increased SIRT2 expression 
in breast cancer cell lines, is in keeping with such a view point. Increased SIRT2 
expression, secondary to radiation-induced chromosomal damage, may confer a survival 
advantage to these cells. This increased transcriptional expression, appears to be 
independent of p53 activity, as increased SIRT2 expression was observed in both types of 
mammary cancer cell line. This confirms previous observations in which Sirt2 was shown 
to regulate radiation-induced cell death in a p53-independent manner in a chicken cell 
line (Matsushita et a l, 2005). The delay in observing increased SIRT2 expression, may 
reflect tumour cell replication leading to an accumulation of cells with chromosomal 
abnormalities. Furthermore, nucleo-cytoplasmic shuttling of Sirt2 also occurs within 24
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hours of exposure to ionising radiation suggesting a possible role for it in the DNA 
damage response (Inoue et a l, 2006). Our data, indicating a delay in the elevation of 
SIRT2 transcription is consistent with such a role.
Similarly, SIRT7 expression also displayed a delayed dose-dependent increase with 
irradiation in both cell lines. As with Sirt2, both Siit6 and Sirt7 closely associate with 
chromosomes during mitosis and, may similarly, participate in a cell-cycle checkpoint. 
Furthermore, Sirt7 may also have a role in the repair of damaged DNA. Indeed, decreased 
levels of Sirt7 are not only associated with decreased cell proliferation but are also 
associated with an increase in apoptotic cell death (Ford et a l, 2006). Conversely, 
increased Sirt7 levels are associated with both cell proliferation and survival. The 
increase in SIRT7 expression observed in the experiments in this chapter, may reflect an 
indirect consequence of cell stress responses, induced to help in cell suiwival or, 
alternatively, may be a direct response to radiation-induced DNA damage and growth 
arrest. This remains to be proven.
The anti-apoptotic sirtuin, SIRTl showed no change in transcriptional expression with 
ionising radiation and, therefore, does not appear to participate in suiwival responses in 
response to radiation in either, the MCF-7 or MDA-MB-231 breast cancer cells. The 
resistance to apoptosis in response to ionising radiation in these cell lines is independent 
of p53 activity and linked to abnormalities in mitochondrial caspase (Essmann et a l, 
2004). Sirtl inhibits apoptosis by interacting with factors upstream fi'om caspase, 
including p53, Ku and E2FI (Luo et al., 2001, Cohen et al., 2004b, Wang et al., 2006).
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Changes in the transcriptional expression of SIRTl would, therefore, still be expected if 
Sirtl functions as a sensor of DNA damage in breast cancer cells. The transcriptional 
expression of SIRTl remained relatively stable with increasing radiation dose suggesting 
that Sirtl does not perform this function in the cell lines studied. This observation is 
supported by studies that have shown deficiencies in SIRTl expression to only impact on 
sensitivity to apoptosis in thymocytes and spermatogonia but not in other tissue (Cheng et 
al., 2003, McBurney et al., 2003).
In both cancer cell lines, SIRT3 expression showed no change in pattern o f expression 
with increasing radiation exposure. This suggests that Sirt3 does not play a role in the 
prevention of radiation-induced damage in either of these cell lines. Although ionising 
radiation results in global cell damage, including that at cell membranes and within 
mitochondria, it primarily causes cell death and growth arrest by the induction of DNA 
damage (Ward, 1988). This may explain the absence of changes in SIRT3 expression in 
the breast cancer cell lines studied. The location of Sirt3 within the mitochondrion and its 
NAD-dependence make it a potential candidate for mediating the apoptotic response 
(Onyango et al., 2002, Schwer et al., 2002). This relationship cannot be confirmed as 
neither cell line displayed radiation-induced apoptosis. It is, therefore, not possible to 
exclude a role for Sirt3 in radiation-induced apoptosis.
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5.7.2 Taxane therapy
Taxols induce apoptosis (Schimming et a l, 1999) as well as mitotic catastrophe, the 
primary mechanism of cell death (Morse et a l, 2005). Sirtuin expression was studied in 
response to paclitaxel exposure, as sirtuins are implicated in both of these processes. 
Increasing expression in the MCF-7 cell line with paclitaxel exposure suggests
that these cells sustained increased damage with increasing paclitaxel dosage. In response 
to cell damage, the p21^^^ cdk inhibitor prevents phosphorylation of pRb, thereby 
repressing expression of cell-cycle genes and resulting in cell-cycle arrest (Samuel et a l, 
2002).
SIRT2 expression displayed a dose-dependent increase with paclitaxel exposure. Taxane 
therapy induce cell damage by microtubule disruption and is associated with increased 
microtubule acétylation (Marcus et a l, 2005). Sirt2 deacetylates microtubules at the M 
phase of the cell-cycle resulting in mitotic arrest. It is hypothesised that, in this way, Sirt2 
prevents cell division in cells harbouring chromosomal abnormalities (Dryden et a l, 
2003). Sirt2 has been shown to prevent microtubule poison-induced hyperploid cell 
formation via a block of entry to chromosome condensation (Inoue et a l, 2006). 
Increased transcriptional expression of SIRT2 may, therefore, be expected after taxane 
treatment. Our data are consistent with this and, in fact show that increased SIRT2 
expression occurs 24 hours after treatment. This may reflect the accumulation of breast 
cancer cells as they undergo replicative cell death.
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Similarly, SIRT7 expression displayed a dose-dependent increase with paclitaxel 
exposure. Sirt7 may also participate in a mitotic check point and cell-cycle control 
(Michishita et a l, 2005), and its increased transcriptional expression may be expected 
after paclitaxel treatment. Sirt7 may also have a role in the repair of DNA damage as 
decreased levels of Sirt7 are associated with apoptotic cell death (Ford et a l,  2006). 
Paclitaxel is known to induce apoptotic as well as non-apoptotic cell death in breast 
cancer cells (Blagosklonny et a l, 2002). This again suggests that increased SIRT7 
expression may be expected in response to paclitaxel exposure. Our data are, again, 
consistent with this and show increased SIRT7 expression to occur after 24 hours. These 
results mirror that for Sirt2 and suggest that Sirt7 may participate in a similar mitotic 
checkpoint (Michishita e ta l,  2005).
SIRTl has been shown to control dmg resistance by regulating the multidrug resistance 
gene, mdrl, in response to anthracycline therapy (Chu et a l, 2005). A correlation with 
SIRTl expression was only observed at low drug levels and was associated with p21^^'^ 
but not caspase-3 expression, suggesting that Sirtl-mediated resistance may only occur at 
sublethal stress levels. Furthermore, increased levels of SIRTl expression were also 
obsei-ved in various types of cancer cell line and tumour biopsy subjected to 
anthracycline, etoposide and cisplatin therapies (Chu et a l, 2005). Treatment with 
paclitaxel may be expected to promote SIRTl transcription, as the mdrl gene is also 
implicated in resistance to paclitaxel in breast cancer (Mechetner et a l, 1998). This was 
not observed and may reflect the very high doses of paclitaxel used. It may be that lower
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levels of paclitaxel treatment, resulting in sub-cytotoxic stress, may be associated with 
SIRTl and mdrl expression.
In MCF-7 cells, paclitaxel exposure can also result in apoptosis via a Foxo3a-dependent 
mechanism (Sunters et a l, 2003). Sirtl increases the ability of Foxo3a to induce cell- 
cycle arrest thereby helping resist oxidative stress and inhibiting apoptosis (Brunet et al., 
2004, Motta et al., 2004, Nemoto et al., 2005). Our data show no change in the 
transcriptional expression o îS IR T l and suggest that Sirtl does not play a part in Foxo3a 
mediated resistance to paclitaxel-induced cell death. This is in keeping with other studies 
that suggest that Sirtl represses Foxo4 rather than Foxo3a-mediated apoptosis (Ford et 
a l, 2005)
SIRT3 did not show any specific pattern of expression with paclitaxel treatment. 
Although paclitaxel can affect the cellular redox state to induce apoptosis (Varbiro et a l, 
2001) its primary mechanism of action is by the microtubular damage and disruption of 
mitotic cell division (Horwitz, 1992). Our data, are in keeping with a scenario, whereby 
Sirt3 is not involved in the paclitaxel damage response and its expression would, 
therefore, not be expected to increase with paclitaxel therapy. The study o f Sirt3 as well 
as of the other mitochondrial sirtuins, Sirt4 and Sirt5, may be of interest in breast cancer 
cells exposed to direct oxidative insult.
These experiments have shown increased transcriptional expression of SIRT2 and SIRT7 
occurs in mammaiy cancer cell lines in response to both irradiation and paclitaxel
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therapy. These results parallel the observations on anti-oestrogens that show increased 
SIRT2, 4 and 7 transcription in breast cancer cells after exposure to these drugs (Reid et 
a l, 2005). This suggests that these damage responses affect sirtuin responses within 
different components of the MTR. These data further suggest that SIRT2 and SIRT7 
expression may be a useful evaluator of breast cancer therapy.
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Chapter 6 
General Discussion
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The aim of the research presented within this thesis was to study breast cancer as an 
aberration of normal biological ageing, with respect to sirtuin expression. It specifically 
sought to determine whether there was an association between the transcriptional 
expression of sirtuins and breast cancer pathogenesis and treatment.
The transcriptional expression of sirtuins was initially investigated in primary and 
immortalised mammary epithelial cells, as a function of in vitro growth (Chapter 3). In 
order to determine whether changes in biological ageing, observed in the primary 
mammary epithelial cells, were pertinent to breast cancer in vivo, transcriptional 
expression of sirtuins was studied in non-malignant and malignant breast tissue biopsies 
(Chapter 4).
Transcriptional studies were also performed to determine the relationship between 
common therapies used for the treatment of breast cancer, namely radiotherapy and 
chemotherapy, and sirtuin expression. Specifically, sirtuin expression was investigated in 
breast cancer cells in response to cellular irradiation and paclitaxel tieatment (Chapter 5).
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6.1 Introduction
In this thesis, breast cancer has been studied as an aberration of normal biological ageing. 
Specifically, using real-time PCR, it has sought to determine whether there was an 
association between the transcriptional expression of sirtuins and breast cancer 
pathogenesis and treatment.
Real-time PCR is a well established, powerful technique that allows the rapid 
transcriptional analysis of a large number of genes (Held et al., 1996). To ensure the 
reproducibility of this technique a number of measures were taken. An internal 
housekeeping reference gene, against which each sample was normalised, was analysed 
for each sample. Negative controls lacking cDNA template as well as primer/probes were 
routinely analysed for each experiment. Validation experiment were initially performed 
to confirm that the efficiencies of the primer/probe sets for both housekeeping gene and 
gene of interest was similar at the range of dilutions used. Furthermore, all samples were 
analysed in duplicate and gave results that showed coefficients of variation of less than 
0.01. Finally, all experiments were performed in duplicate.
These measures ensured that the results from the transcriptional studies were truly 
representative for our breast cancer experiments.
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6.2 Sirtuins, senescence and breast cancer
The study of breast cancer biology has traditionally focused on transformation as a result 
of abnormalities in normal growth and proliferation. The study of this disease as an 
aberration of biological ageing provides an alternative platform for understanding breast 
cancer. Components of the MTR, are inextricably linked and allow the cell to tie damage 
responses to energy production, fuel utilisation and protein synthesis (Shiels and Davies, 
2003). Furthermore, aberrations in any one of these may contribute to ageing-related 
diseases, including cancer. The study of sirtuins, genes that link components of the MTR, 
is informative in this context (Sklavounou et al., 2006).
This thesis has demonstrated that sirtuins, associated with individual components of the 
MTR, show changes in transcription with mammary epithelial cell senescence. This has 
been demonstrated for SIRT3 and SIRT7 in primary mammary epithelial cell senescence. 
As with yeast Sir2, nucleolar levels of Sirt7 may determine when cells become senescent. 
Although Sirt7 activates Pol I-mediated rRNA transcription, thereby encouraging growth 
and proliferation (Ford et a l, 2005), senescent cells have been shown to exhibit a higher 
rate of rRNA synthesis compared to younger cells (Halle et a l, 1997). Increasing SIRT7 
expression may reflect increased rRNA synthesis that occurs in senescent cells. In 
addition, rRNA transcription may also act as a direct sensor for accumulation of DNA 
damage over a cell’s lifespan (Shiels and Davies, 2003). These data are consistent with 
those of Ford et a l (2006), that showed increased levels of Sirt7 to be associated with
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growth and proliferation and decreased levels of Sirt7 with growth arrest and apoptosis 
(Ford et a i, 2006).
Sirt3 is implicated in mitochondrial energy production and fuel utilisation in times of 
stress. In particular, high levels of Sirt3 are observed in starvation and diabetic 
ketogenesis (Hallows et a l, 2006). Cells undergoing stresses inherent in replicative 
ageing are unable to utilise fuel efficiently and increased SIRT3 expression may occur as 
a compensatory mechanism to counter this (Onyango et al., 2002, Schwer et al., 2002). 
Our data support this view, with increased SIRT3 transcriptional expression being 
observed in replicative ageing mammary epithelial cells. These changes may result in 
increased efficiency of fuel utilisation and energy production in an attempt to prolong 
lifespan as cells age. This is further supported by in vivo studies that have shown 
increased SIRT3 expression to be associated with longevity (Bellizzi et al., 2005, Rose et 
al., 2003).
The changes in sirtuin expression in replicatively ageing mammary epithelial cells 
parallel those observed in the breast cancer biopsies. The data in this thesis showed SIRT7 
expression to be higher in breast cancer biopsies compared to non-malignant breast 
biopsies. This result mirrors the observation that increased SIRT7 expression is a feature 
of thyroid cancer (de Nigris et al., 2002, Frye, 2002). Furthermore, subdividing breast 
cancer biopsies by lymph node status revealed that increased expression of both SIRT3 
and SIRT7 is associated with prognostically poorer lymph node positive disease. The 
research in this thesis has, for the first time, indicated that increased expression of these
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sirtuins may provide mammary epithelial cells with a survival advantage and thereby 
contribute to breast tumorogenesis. These data also suggest that increased sirtuin 
expression may reflect the greater degree of biological ageing that occurs in breast 
cancers, despite the ability of tumour cells to continue proliferating. The increased 
expression of SIRT3 and SIRT7 observed in lymph node positive breast cancers indicates 
that tumours that are more aggressive and have the worse prognosis display the most 
biological ageing.
The expression of SIRTl and SIRT2, sirtuins associated with senescence and certain 
tumour types, was not found to be different in ageing mammary epithelial cells or 
between non-malignant and malignant breast tissue, at the transcriptional level. These 
data contrast with the observations that altered expression of these sirtuins is a feature of 
certain other malignancies (Luo et al., 2001, Lim, 2006b, Yeung et al., 2004, Kuzmichev 
et al., 2005, Chen et al., 2005, Hiratsuka et al., 2003, Inoue et al., 2006). Despite this, the 
role for these sirtuins in cancer pathogenesis is by no means clear, as their expression is 
not altered in a number of other malignancies (Lim, 2006b). Likewise, our data suggest 
that these sirtuins are not implicated in biological ageing in mammary epithelial cells or 
in breast cancer pathogenesis. These results must, however, be interpreted within the 
context of a transcriptional study of limited size. Increasing the number of biopsies 
studied and performing post-transcriptional studies may help to confirm these results.
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6.3 Sirtuins and breast cancer therapy
Therapies commonly used for the treatment of breast cancer often induce senescence and 
apoptosis, processes that also contribute to the pathogenesis of ageing-related diseases 
(Shay and Roninson, 2004, Chang et al., 1999, Ota et al., 2006, Chu et al., 2005). The 
ability of breast cancer cells to withstand the insult of cytotoxic therapies may, therefore, 
be influenced by the expression of sirtuins; genes involved in DNA repair, cell-cycle 
regulation and ageing (Mostoslavsky et al., 2006, Diyden et al., 2003, Howitz et al., 
2003). Cancer therapies can affect the different components of the MTR, by inducing 
DNA and telomeric damage, cell-cycle arrest and interfering with mitochondrial energy 
production and protein synthesis (Russo and Russo, 2003). The sirtuins that link 
individual components of the MTR may, therefore, be useful in evaluating breast cancer 
therapies (Sklavounou et al., 2006).
A role for sirtuins in promoting cell survival in response to stress is suggested by our 
data, that showed changes in sirtuin expression in breast cancer cells after exposure to 
cytotoxic agents. Specifically, evaluation of individual sirtuins indicated that SIRT2 and 
SIRT7 expression was associated with cell damage from both ionising radiation and 
paclitaxel treatment.
The increased SIRT2 expression observed is consistent with a scenario whereby increased 
chromosomal abnormalities occur as a result of irradiation and paclitaxel therapy (Suzuki 
et al., 2003, Pawlik and Keyomarsi, 2004, Piperno et al., 1987). Sirt2 is involved in the M
149
phase cell-cycle checkpoint and may function to arrest the cell-cycle in response to 
chromosomal abnormalities (Dryden et al., 2003, Inoue et al., 2006). The nucleo- 
cytoplasmic shuttling of Sirt2 in response to ionising radiation also suggest a possible 
role for it in the DNA damage response. Treatment of gliomas and gastric cancers with 
histone deacetylase inhibitors, results in tumour cell death and is associated with 
increased SIRT2 expression (Inoue et a l, 2006). Furthermore, increased SIRT2 
expression is associated with puromycin-induced cell death (Grubisha et a l, 2006). Our 
data also demonstrated an increase in SIRT2 expression in breast cancer cells, after 
irradiation and paclitaxel treatment and is supportive of a role for Sirt2 in the damage 
response. These observations suggest that targeting Sirt2, a protein that participates in 
mitotic control and possibly DNA damage responses, may provide therapeutic benefit.
The increased levels of SIRT7 expression observed may reflect stresses experienced by 
damaged cancer cells suffering replicative death and unable to proliferate as a result of 
these therapies. In particular, the increase in SIRT7 expression after these cytotoxic 
agents may reflect accelerated ageing as a result of these treatments (Shiels and Davies, 
2003). This is analogous to the increased SIRT7 expression observed in mammaiy 
epithelial cells as they undergo replicative ageing. In addition, the repetitive nature of the 
I’RNA genes provides a high probability of a polymerase encountering, and stalling at 
sites of DNA damage (Russell and Zomerdijk, 2005). The accumulation of signals 
associated with such stalled DNA polymerases may activate DNA-damage response 
pathways that contribute to apoptosis and growth arrest. The data in this thesis, showing
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increased S1RT7 expression, and as a consequence, increased rRNA transcription, is 
supportive of this.
Altered SIRT2 and SIRT7 expression have previously been shown to be associated with 
microtubule disrupting drugs, cisplatin therapy and anti-oestrogen therapy (Matsushita et 
a l, 2005, Kyrylenko et a l, 2003, Inoue et a l, 2006). Our findings have shown that these 
same sirtuins are also good evaluators of irradiation and paclitaxel therapy in breast 
cancer.
The lack of changes in SIRTl and SIRT3 expression in breast cancer cells subjected to 
irradiation and paclitaxel treatment, suggest that these sirtuins are not implicated in 
damage responses as a result o f these therapies. Although the cell’s response to these 
treatments include apoptosis, their primary mode of action is by inducing replicative cell 
death (Steel, 2001, Pawlik and Keyomarsi, 2004, Blagosklonny et a l, 2002). Indeed, our 
data have confirmed that apoptosis is not the principal method of death in the irradiated 
breast cancer cells used in this study, and have, for the first time, shown that increased 
SIRT2 and SIRT7 expression occurs in irradiated mammary epithelial cells in a p53- 
independent manner. These observations do not, however, exclude a role for Sirtl and 
Sirt3 in the response of breast cancer cells to these treatments. This was a transcriptional 
study and it may be that performing post-translational studies show that changes in 
sirtuins are reportive of these therapies. Studying breast cancer treatments that primarily 
induce apoptosis may also shed light on the role of sirtuins, in particular of the anti- 
apoptotic Sirtl, in protecting against these therapies.
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Furthermore, inhibition of sirtuin activity with the Sirtl inhibitor, Sirtinol, has been 
shown to induce senescent growth arrest in human breast and lung cancer cells (Ota et a i, 
2005). This may act, not only by targeting tumour cells that may have upregulated SIRTl 
in order to achieve transformation, but also by sensitising tumour cells to p53-mediated 
senescence and apoptosis (Luo et al., 2001, Heltweg et al., 2006). A recent study has also 
shown that inhibition of Sirtl causes the reactivation of silenced genes in cancer cells 
resulting in growth arrest (Pruitt et a l,  2006). Paradoxically, the sirtuin activator, 
resveratrol, has also been shown to beneficial in the treatment of cancer and has been 
shown to induce tumour cell apoptosis (Signorelli and Ghidoni, 2005). This has been 
shown to occur via Sirtl-mediated augmentation of TNFa-mediated tumour cell 
apoptosis (Yeung et a l, 2004).
The association between sirtuin expression in breast cancer biopsies as well as its 
relationship to breast cancer therapy raises the question as to whether targeting of sirtuins 
may be beneficial in the treatment of the disease. Previously, Sirtl has been shown to be 
essential for cancer cell viability but not for non-cancer cell viability (Ford et a l,  2005). 
Furthermore, overexpression of SIRTl has been shown to be a feature of drug-resistant 
cancer cell lines and tumour biopsies fi'om patients subjected to chemotherapy (Chu et 
a l, 2005). Sirtl may therefore be a selective target in tumour cells. Similarly, other 
sirtuins, in particular Sirt2, 3 and 7, may also be selective targets in breast cancer.
Already, histone deacetylase inhibitors (HDACi) have been shown to exert anti-tumour 
effects and are undergoing phase II clinical trials (Lin et al., 2006, Carey and La
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Thangue, 2006, Marks et al., 2001). HDACi that target sirtuins have also been shown to 
induce senescence in a number of cancers including breast and lung cancer (Ota et al,, 
2005, Porcu and Chiarugi, 2005). These drugs are not selective for Sirtl and may mediate 
their effects by inhibiting the activity of other sirtuins. The data in this thesis is 
supportive of such as notion.
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6,4 Future work
In the study of sirtuins in replicative ageing and breast biopsies, the transcriptional 
expression of Sirtuins 4, 5 and 6 have yet to be examined. Sirt6 is particularly interesting 
as it has been shown to participate in DNA damage repair and its deletion in transgenic 
mice results in a progeroid syndrome (Mostoslavsky et a l, 2006). Sirt4 is a mitochondrial 
sirtuin that is implicated in fuel utilisation and insulin metabolism in response to calorie 
restriction (Haigis et a l, 2006). SirtS, also a mitochondrial sirtuin, may have a similar 
role, or like Sirtl, may participate in resistance to oxidative stress. The analysis of these 
genes may provide insight into the role of sirtuins in mammary epithelial cell senescence 
and breast cancer.
These sirtuins may also play a role in the response of mammary cancer cells to the breast 
treatments studied as well as other treatments commonly used in breast cancer. The 
discoveiy that the transcriptional expression of sirtuins is altered in response to anti- 
oestrogenic treatments in breast cancer cells, suggests that these sirtuins may also 
participate in tumour cell damage responses (Kyrylenko et a l, 2003). The role of Sirt6 in 
assisting DNA repair is supportive of this (Mostoslavsky et a l, 2006).
The role of Sirtl in mediating apoptosis in breast cancer cells in response to ionising 
radiation has not been fully investigated, as cell lines studied displayed resistance to 
radiation-induced apoptosis. Repeating the experiments in a mammary cancer cell line 
that displays radiation-induced apoptosis may clarify the roles of sirtuins in this process.
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The MCF-7 cell line was used to study the effect of paclitaxel on the transcriptional 
expression of sirtuins in breast cancer. This cell line is a good in vitro representative of 
ER positive breast cancer. This type of tumour is normally treated with hormone therapy 
although chemotherapy may also be used if the patient has node positive disease. 
Chemotherapy, however, is usually administered to patients with ER negative or ERBB2 
positive disease. It would, therefore, also be of value to study the effect of paclitaxel on 
the transcriptional expression of sirtuins in both ER negative and ERBB2 positive cell 
lines.
It would be also be interesting to determine the role of sirtuin activators, such as 
resveratrol, as well as sirtuin inhibitors, such as sirtinol and nicotinamide, on sirtuin 
expression, survival and apoptosis in breast cancer cells. Although the activity of these 
agents is not specific to sirtuins it may provide an interesting study on the role of human 
sirtuins in breast cancer. Specific targeting of sirtuins using siRNA may provide a more 
accurate way of determining the role of these sirtuins in breast cancer therapy.
Finally, whilst these studies of sirtuins in breast cancer have been transcriptional, it would 
be interesting to investigate the changes in sirtuin protein expression, as changes in 
mRNA do not necessarily reflect changes in protein expression.
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6.5 Concluding remarks
Prior to the start of this study, sirtuins were not associated with malignancy or cancer 
treatment. In this study, I have presented data that show changes in sirtuin expression to 
be a feature of replicative ageing in mammaiy epithelial cells and breast cancer. 
Furthermore, changes in sirtuin expression have been shown to be associated with 
common therapies used to treat this condition. This transcriptional analysis of sirtuins in 
breast cancer has added to our understanding of breast cancer biology and may help in 
identifying new ways for managing the disease.
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(i) Tissue culture and all molecular work were performed in the Department of 
Surgery, Western Infirmary, University o f Glasgow, Taqman PCR was performed 
on an ABI Prism 7700 sequence detector in the Department of Immunology, 
Western Infirmary, Glasgow. Cellular irradiation and Apoalert TUNEL assays were 
performed at the Department o f Radiation Oncology at the Cancer Research UK, 
Beatson Laboratories, Garscube, Glasgow.
(ii) All work was carried out by myself, however cellular irradiation was performed 
with the assistance of Lesley Wilson and Anne Green from the Department of 
Radiation Oncology at the Cancer Research UK, Beatson Laboratories, Garscube, 
Glasgow.
(iii) Research funding was obtained from the Marjorie Wilkinson Bequest and 
supervision from Dr Paul Shiels, Department of Surgery, Glasgow Royal Infirmaiy, 
Glasgow. Adviser of studies was Professor WD George, Western Infirmary, 
Glasgow.
(iv) Ethical approval for work on archival human breast biopsies was obtained from the 
West of Scotland Ethics Committee.
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Western Analyses
In addition to the transcriptional studies described, studies on sirtuin protein were also 
attempted. Unfortunately, problems were encountered with the human anti-Sirtl antibody 
obtained from Abeam. A number of experiments were performed but, unfoi'tunately, gave 
no interpretable results.
The anti-Sirtl antibody was found to be non-specific, giving a great deal of background 
staining on western analyses. Specifically, two distinct bands of lOOkDa and 160kDa 
could be discerned. These did not match the expected weight of Sirtl (120kDa). 
Furthermore, the detection of these particular bands was not always reproducible even 
within the same protein sample.
On approaching Abeam and reviewing technical enquiries relating to this antibody, it was 
found that others had experienced similar problems. Abeam acknowledged that their 
original antibody was non-specific and in some cases did not work at all. Since 
completing my research, Abeam have produced a new anti-Sirtl antibody and numerous 
other anti-Sirtl antibodies have come onto the market including those from Santa Cruz, 
Upstate and Everest Biotech.
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Senescence data (Chapter 3)
Real-time PCR
G ene P16 P21 SIRT1
P a ssa g e /  
Cell Line 1 2 3 1 2 3 1 2 3
HMEC 0.8467 2.2736 2.7511 0.9461 1.7715 2.3295 1.0570 1.7471 1.4743
1.1810 2 .0350 3.3870 1.0570 1.5210 2.0420 0.9461 2.3376 1.5911
MCF-12A 0.0001 0 .0003 0.0000 1.0461 0.7397 0.8123 1.1057 1.6644 1.3195
0.0000 0 .0000 0 .0000 0 .6902 0.3673 0.5249 1.4093 1.4489 1.6702
MGF-7 0.0001 0.0001 0.0000 0 .4132 0 .3724 0.6974 1.8340 1.8987 1.8150
0 .0000 0.0000 0.0000 0.5017 0.4368 0.6029 1.1851 1.2269 1.4540
G ene SIRT2 SIRT3 SIRT7
P a ssa g e /  
Cell Line 1 2 3 1 2 3 1 2 3
HMEC 1.0607 2.4623 1.6077 0.6462 2.2579 3.2490 0.5529 2.0420 4 .6107
0.9428 2.0849 1.5966 1.5476 2.1067 2.5669 1.8088 3 .8637 7.3871
MCF-12A 1.8404 0.9138 3.0420 0.8796 0.8796 1.2658 1.3379 1.3013 1.9386
2.3784 0.7320 2 .4368 1.0755 1.4290 1.8404 1.0792 2 .5669 1.9119
MCF-7 2.0420 1.4241 2.4368 1.3613 0.6395 1.5263 0.9266 0.5743 0.3046
2.6390 1.1408 3.1492 0.9897 0.8039 0.7579 1.3566 0 .6926 0.3909
SA (3-Gal Assay
P a ssa g e /  
Cell Line 1 2 3
HMEC 15 38 79
20 43 82
MCF-12A 24 22 25
30 28 27
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Biopsy data (Chapter 4)
G ene/ 
Cell Line SIRT1 SIRT2 SIRT3 SIRT7
Cancer 1 0 .572362 0 .959264 0.410371 1 .090508
C ancer 2 0.993092 1.197479 1.128964 0 .949342
Cancer 3 0.655197 0.366021 0.526681 2 .034959
Cancer 4 0 .301452 0.712025 0.590496 2 .566852
Cancer 5 1.22264 0 .861546 0 .675955 1.993081
Cancer 6 0 .063153 0.162668 0,281265 2 .522755
C an cer? 0.345079 2 .281527 0 .271684 1.180993
Cancer 8 0 .986233 0 .64842 0 .617709 1.681793
C ancer 9 0 .867539 0 .712025 0 .809442 2.313376
Cancer 10 0 .537747 0 .76313 0 .449066 0 .920188
Cancer 11 1.090508 0.750019 0 .435275 0 .879649
C ancer 12 0.732043 1.185093 0 .369847 1.438934
C ancer 13 0.150205 0.582367 0 .133508 0.768438
C ancer 14 0.259715 0.650671 0.408951 1.060688
Cancer 15 0 .939523 1 .324089 0 .464902 1.652901
Cancer 16 0.098413 0.17254 0 .135842 0 .867539
C ancer 17 0.143091 0 .417544 0.153361 0 .755236
Cancer 18 1.000000 1.000000 1.000000 1.000000
Cancer 19 0 .367292 0 .269807 0 .524858 0 .923382
Cancer 20 0 .316439 3 .149232 0.396392 1.840375
Cancer 21 0 .075102 0 .476319 0.079937 0 .760489
Cancer 22 0 .747425 0 .732043 0 .564482 1.443929
Cancer 23 0 .336808 0 .578344 0 .812252 1.484524
Cancer 24 0.421908 1.265757 0.5 2 .61172
Non-malignant 1 0 .464902 0.643941 0.316439 0 .673617
Non-malignant 2 0 .855595 1.510473 0 .447513 0.61132
Non-malignant 3 0.685391 0 .473029 0 .240649 0 .369847
Non-malignant 4 0 .795536 0.716978 0 .406126 0 .486327
Non-malignant 5 0.403321 0.650671 0 .240649 0.574349
Non-malignant 6 0 .496546 0.643941 0.067921 0 .898132
Non-malignant 7 0.517632 1.558329 0.37501 1.028114
Non-malignant 8 1.292353 1.226885 0.283221 0 .726986
Non-malignant 9 0 .91067 1.22264 0 .313166 0 .809442
Non-malignant 10 0.528509 1.536875 0.479632 1.105731
Non-malignant 11 0.835088 0 .933033 0.600818 0 .882703
Non-malignant 12 1.257013 0 .972655 0 .427798 1.252664
Non-malignant 13 0 .855595 0.823591 0.469761 0.846745
Non-malignant 14 0 .707107 1.270151 0 .707107 1.433955
Non-malignant 15 0 .668964 0.607097 0 .639493 1 .399586
Non-malignant 16 0 .271684 0.580352 0 .369847 1.090508
Non-malignant 17 1.464086 0.852635 0 .989657 1.226885
Non-malignant 18 0 .095722 0.174343 0 .108442 0.332171
Non-malignant 19 0 .353553 0.750019 0.185565 0.261521
Non-malignant 20 1.265757 0.768438 0.494828 1.003472
Non-malignant 21 0 .346277 0.503478 0.146097 0 .493116
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Irradiation data (Chapter 5)
MCF-7 cell line
G ene
Radiation 
D o se  (Gys)/ 
Time
0 2 4 6 8 10
P21 24hrs 1.0000 0.8615 1.3660 1.7901 2 .6574 3.1383
1.0000 1.0317 2.1585 2 .4880 3.5801 3.8371
48hrs 0.5529 0.9107 1.9386 2 .9180 3 .8504 4.6428
0 .4005 0.7022 1.0644 1.8921 3.1275 4 .1554
SIRT1 24hrs 1.0000 0.7711 0.4730 0.8497 0,9526 1.0792
1.0000 1.0105 1.3195 1.0867 1.1933 1.4743
48hrs 0.2726 0.8888 1.6935 0 .7448 1.3472 0.9138
1.1851 1.0905 0.5141 1.3660 0.8322 1.1607
SIRT2 24hrs 1.0000 0.7071 0.9461 1.1607 1.4191 1.7112
1.0000 1.3519 1.5529 0.6998 5.2054 2.9383
48hrs 1.7291 2.0350 2.7132 2.6027 2 .8284 3.1492
1.1975 1.3803 1.8661 1.8468 3.3288 2.6759
SIR Ï3 24hrs 1.0000 0.2588 0 .2994 0.2932 0.4538 0.3737
1.0000 1.1607 1.2184 0.6807 0.8950 0.6760
48hrs 0.3869 0.4175 0.6598 0.4649 0.4601 0.6439
0.6071 0.6199 1.0140 0.6926 1.1975 0.8151
S1RT7 24hrs 1.0000 1.3566 1.1975 1.2100 1.3059 1.7471
1.0000 1.5105 1.7839 0.8796 1.3059 1.7901
48hrs 1.8340 2.4623 3.6808 3.0738 4.4076 4.6913
1.7777 2.0209 2.7511 2.6759 4.2871 4.9417
MDA-MB-231 cell line
G ene
Radiation 
D ose (Gys)/ 
Time
0 2 4 6 8 10
P21 24hrs 1.0000 1.0534 0.9428 1.1487 0.8645 0.8236
1.0000 1.0000 1.2058 1.4191 1.4743 1.4389
48hrs 1.0353 0.8950 0.9693 1.1527 1.7777 1.4340
1.2058 1.2702 1.5369 1.2397 1.5801 1.7112
SIRT1 24hrs 1.0000 0.5141 0.3572 0.4763 0.5141 0.8236
1.0000 1.1728 1.6818 1.8213 0.8011 1.1810
48hrs 1.5422 2.2736 0.9428 0.7955 1.2614 1.0425
2 .0777 2.4794 2.6117 2.0279 2.5403 2.0139
SIRT2 24hrs 1.0000 1.2879 1.7053 1.5856 1.3851 2.0994
1.0000 0.5000 0.8645 1.1251 0.9931 1.3013
48hrs 1.5583 1.6644 1.6818 1.6133 2.6027 2.4453
1.3149 1.0534 0,9931 1.5801 1.6935 2.5053
SIRT3 24hrs 1.0000 0.5070 0.3451 0.4506 0.4830 0.7928
1.0000 0.7397 1.1290 1.2879 0.8615 0.8950
48hrs 1.4540 2.0922 0.8766 0.7071 1.2527 0.9897
1.5476 0.7846 1.8340 0.8526 0.9897 1.0281
SIRT7 24hrs 1.0000 1.0718 0.7900 0.9559 0.7765 1.3613
1.0000 0.3403 0.4897 0.9170 0.6666 1.0534
48hrs 1.0867 1.2790 1.2570 1.6077 1.9119 2.3538
0.5340 1.0070 0.7684 1.0070 1.6586 2.9690
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Paclitaxel data (Chapter 5)
Paclitaxel
Concentration
(ng/ml)/
G ene
0 0.01 0.1 1 10
P21 1.0000 1.1607 2 .4538 4.4229 7.9173
1.0000 2 .1962 2 .6208 3.5677 5.2964
SIRT1 1.0000 0.6736 1.8404 0.6113 1.0210
1.0000 1.7593 0 .7270 0.6462 1.3013
SIRT2 1.0000 2.0279 2.9282 3.8637 7.0128
1.0000 1.1610 2.3702 3.0951 5.9587
SIRT3 1.0000 1.0175 1.2142 0.9461 1.0425
1.0000 0 .8766 0.7500 0.8293 1.0681
SIRT7 1.0000 3.7451 4.5948 6.2550 8.7543
1.0000 2 .2894 2.7321 5.1515 7.1107
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